000144366912-312024Q3falseP3Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesiso4217:EURxbrli:pure00014436692024-01-012024-09-3000014436692024-10-2800014436692024-09-3000014436692023-12-3100014436692024-07-012024-09-3000014436692023-07-012023-09-3000014436692023-01-012023-09-300001443669us-gaap:CommonStockMember2023-12-310001443669us-gaap:AdditionalPaidInCapitalMember2023-12-310001443669us-gaap:RetainedEarningsMember2023-12-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001443669us-gaap:CommonStockMember2024-01-012024-03-310001443669us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100014436692024-01-012024-03-310001443669us-gaap:RetainedEarningsMember2024-01-012024-03-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001443669us-gaap:CommonStockMember2024-03-310001443669us-gaap:AdditionalPaidInCapitalMember2024-03-310001443669us-gaap:RetainedEarningsMember2024-03-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100014436692024-03-310001443669us-gaap:CommonStockMember2024-04-012024-06-300001443669us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000014436692024-04-012024-06-300001443669us-gaap:RetainedEarningsMember2024-04-012024-06-300001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001443669us-gaap:CommonStockMember2024-06-300001443669us-gaap:AdditionalPaidInCapitalMember2024-06-300001443669us-gaap:RetainedEarningsMember2024-06-300001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000014436692024-06-300001443669us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001443669us-gaap:CommonStockMember2024-07-012024-09-300001443669us-gaap:RetainedEarningsMember2024-07-012024-09-300001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001443669us-gaap:CommonStockMember2024-09-300001443669us-gaap:AdditionalPaidInCapitalMember2024-09-300001443669us-gaap:RetainedEarningsMember2024-09-300001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001443669us-gaap:CommonStockMember2022-12-310001443669us-gaap:AdditionalPaidInCapitalMember2022-12-310001443669us-gaap:RetainedEarningsMember2022-12-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100014436692022-12-310001443669us-gaap:CommonStockMember2023-01-012023-03-310001443669us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100014436692023-01-012023-03-310001443669us-gaap:RetainedEarningsMember2023-01-012023-03-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001443669us-gaap:CommonStockMember2023-03-310001443669us-gaap:AdditionalPaidInCapitalMember2023-03-310001443669us-gaap:RetainedEarningsMember2023-03-310001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100014436692023-03-310001443669us-gaap:CommonStockMember2023-04-012023-06-300001443669us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000014436692023-04-012023-06-300001443669us-gaap:RetainedEarningsMember2023-04-012023-06-300001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001443669us-gaap:CommonStockMember2023-06-300001443669us-gaap:AdditionalPaidInCapitalMember2023-06-300001443669us-gaap:RetainedEarningsMember2023-06-300001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000014436692023-06-300001443669us-gaap:CommonStockMember2023-07-012023-09-300001443669us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001443669us-gaap:RetainedEarningsMember2023-07-012023-09-300001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001443669us-gaap:CommonStockMember2023-09-300001443669us-gaap:AdditionalPaidInCapitalMember2023-09-300001443669us-gaap:RetainedEarningsMember2023-09-300001443669us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000014436692023-09-300001443669us-gaap:MarketingRelatedIntangibleAssetsMember2024-09-300001443669us-gaap:MarketingRelatedIntangibleAssetsMember2023-12-310001443669us-gaap:NoncompeteAgreementsMember2024-09-300001443669us-gaap:NoncompeteAgreementsMember2023-12-310001443669us-gaap:NoncompeteAgreementsMembersrt:MinimumMember2024-09-300001443669us-gaap:NoncompeteAgreementsMembersrt:MaximumMember2024-09-300001443669us-gaap:ComputerSoftwareIntangibleAssetMember2024-09-300001443669us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001443669prlb:SoftwarePlatformMember2024-09-300001443669prlb:SoftwarePlatformMember2023-12-310001443669us-gaap:TradeNamesMember2024-09-300001443669us-gaap:TradeNamesMember2023-12-310001443669us-gaap:CustomerRelationshipsMember2024-09-300001443669us-gaap:CustomerRelationshipsMember2023-12-310001443669us-gaap:CustomerRelationshipsMembersrt:MinimumMember2024-09-300001443669us-gaap:CustomerRelationshipsMembersrt:MaximumMember2024-09-300001443669srt:EuropeMemberprlb:A3DHubsInc.HubsMember2021-01-222021-01-220001443669country:USprlb:A3DHubsInc.HubsMember2021-01-222021-01-2200014436692023-01-012023-12-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-09-300001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-09-300001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-09-300001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2023-12-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2023-12-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2023-12-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001443669us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001443669us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001443669us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001443669us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001443669us-gaap:CorporateDebtSecuritiesMember2024-09-300001443669us-gaap:USStatesAndPoliticalSubdivisionsMember2024-09-300001443669us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001443669us-gaap:CorporateDebtSecuritiesMember2023-12-310001443669us-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310001443669us-gaap:BankTimeDepositsMember2023-12-310001443669prlb:LongTermIncentivePlan2022Member2024-05-232024-05-230001443669prlb:LongTermIncentivePlan2022Member2024-01-012024-09-300001443669prlb:ESPPMember2024-01-012024-09-300001443669us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001443669us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-09-300001443669us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-09-300001443669us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-01-012023-09-300001443669us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-01-012023-09-300001443669us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001443669us-gaap:EmployeeStockOptionMember2024-09-300001443669us-gaap:RestrictedStockMembersrt:MinimumMember2024-01-012024-09-300001443669us-gaap:RestrictedStockMembersrt:MaximumMember2024-01-012024-09-300001443669us-gaap:RestrictedStockMember2023-12-310001443669us-gaap:RestrictedStockMember2024-01-012024-09-300001443669us-gaap:RestrictedStockMember2024-09-300001443669us-gaap:PerformanceSharesMember2024-09-300001443669us-gaap:PerformanceSharesMember2024-01-012024-09-300001443669us-gaap:PerformanceSharesMember2023-12-310001443669us-gaap:PerformanceSharesMember2023-01-012023-09-300001443669prlb:EmployeeStockPurchasePlanMembersrt:MinimumMember2024-01-012024-09-300001443669prlb:EmployeeStockPurchasePlanMembersrt:MaximumMember2024-01-012024-09-300001443669prlb:EmployeeStockPurchasePlanMembersrt:MinimumMember2023-01-012023-09-300001443669prlb:EmployeeStockPurchasePlanMembersrt:MaximumMember2023-01-012023-09-300001443669prlb:EmployeeStockPurchasePlanMember2024-01-012024-09-300001443669prlb:EmployeeStockPurchasePlanMember2023-01-012023-09-300001443669us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300001443669us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300001443669us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300001443669us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300001443669us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-012024-09-300001443669us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012023-09-300001443669us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-09-300001443669us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300001443669us-gaap:OperatingSegmentsMemberprlb:UnitedStatesSegmentMember2024-07-012024-09-300001443669us-gaap:OperatingSegmentsMemberprlb:UnitedStatesSegmentMember2023-07-012023-09-300001443669us-gaap:OperatingSegmentsMemberprlb:UnitedStatesSegmentMember2024-01-012024-09-300001443669us-gaap:OperatingSegmentsMemberprlb:UnitedStatesSegmentMember2023-01-012023-09-300001443669us-gaap:OperatingSegmentsMemberprlb:EuropeSegmentMember2024-07-012024-09-300001443669us-gaap:OperatingSegmentsMemberprlb:EuropeSegmentMember2023-07-012023-09-300001443669us-gaap:OperatingSegmentsMemberprlb:EuropeSegmentMember2024-01-012024-09-300001443669us-gaap:OperatingSegmentsMemberprlb:EuropeSegmentMember2023-01-012023-09-300001443669us-gaap:OperatingSegmentsMember2024-07-012024-09-300001443669us-gaap:OperatingSegmentsMember2023-07-012023-09-300001443669us-gaap:OperatingSegmentsMember2024-01-012024-09-300001443669us-gaap:OperatingSegmentsMember2023-01-012023-09-300001443669us-gaap:OperatingSegmentsMemberprlb:CorporateUnallocatedAndJapanSegmentMember2024-07-012024-09-300001443669us-gaap:OperatingSegmentsMemberprlb:CorporateUnallocatedAndJapanSegmentMember2023-07-012023-09-300001443669us-gaap:OperatingSegmentsMemberprlb:CorporateUnallocatedAndJapanSegmentMember2024-01-012024-09-300001443669us-gaap:OperatingSegmentsMemberprlb:CorporateUnallocatedAndJapanSegmentMember2023-01-012023-09-300001443669us-gaap:OperatingSegmentsMemberprlb:UnitedStatesSegmentMember2024-09-300001443669us-gaap:OperatingSegmentsMemberprlb:UnitedStatesSegmentMember2023-12-310001443669us-gaap:OperatingSegmentsMemberprlb:EuropeSegmentMember2024-09-300001443669us-gaap:OperatingSegmentsMemberprlb:EuropeSegmentMember2023-12-310001443669us-gaap:OperatingSegmentsMember2024-09-300001443669us-gaap:OperatingSegmentsMember2023-12-310001443669prlb:InjectionMoldingProtomoldMember2024-07-012024-09-300001443669prlb:InjectionMoldingProtomoldMember2023-07-012023-09-300001443669prlb:InjectionMoldingProtomoldMember2024-01-012024-09-300001443669prlb:InjectionMoldingProtomoldMember2023-01-012023-09-300001443669prlb:CNCMachiningFirstcutMember2024-07-012024-09-300001443669prlb:CNCMachiningFirstcutMember2023-07-012023-09-300001443669prlb:CNCMachiningFirstcutMember2024-01-012024-09-300001443669prlb:CNCMachiningFirstcutMember2023-01-012023-09-300001443669prlb:ThreeDPrintingFinelineMember2024-07-012024-09-300001443669prlb:ThreeDPrintingFinelineMember2023-07-012023-09-300001443669prlb:ThreeDPrintingFinelineMember2024-01-012024-09-300001443669prlb:ThreeDPrintingFinelineMember2023-01-012023-09-300001443669prlb:SheetMetalMember2024-07-012024-09-300001443669prlb:SheetMetalMember2023-07-012023-09-300001443669prlb:SheetMetalMember2024-01-012024-09-300001443669prlb:SheetMetalMember2023-01-012023-09-300001443669prlb:OtherProductsMember2024-07-012024-09-300001443669prlb:OtherProductsMember2023-07-012023-09-300001443669prlb:OtherProductsMember2024-01-012024-09-300001443669prlb:OtherProductsMember2023-01-012023-09-300001443669us-gaap:SubsequentEventMembersrt:MinimumMember2024-10-210001443669us-gaap:SubsequentEventMembersrt:MaximumMember2024-10-210001443669us-gaap:EmployeeSeveranceMemberus-gaap:SubsequentEventMembersrt:MinimumMember2024-10-210001443669us-gaap:EmployeeSeveranceMemberus-gaap:SubsequentEventMembersrt:MaximumMember2024-10-210001443669us-gaap:FacilityClosingMemberus-gaap:SubsequentEventMembersrt:MinimumMember2024-10-210001443669us-gaap:FacilityClosingMemberus-gaap:SubsequentEventMembersrt:MaximumMember2024-10-210001443669srt:ScenarioForecastMember2024-10-012024-12-310001443669us-gaap:EmployeeSeveranceMembersrt:MinimumMembersrt:ScenarioForecastMember2024-10-012025-09-300001443669us-gaap:EmployeeSeveranceMembersrt:MaximumMembersrt:ScenarioForecastMember2024-10-012025-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 10-Q
(Mark One)
þQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission File Number: 001-35435
Proto Labs, Inc.
(Exact name of registrant as specified in its charter)
Minnesota41-1939628
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
5540 Pioneer Creek Drive
Maple Plain, Minnesota
55359
(Address of principal executive offices)(Zip Code)
(763) 479-3680
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, Par Value $0.001 Per SharePRLBNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þYes oNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). þYes oNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerþAccelerated filer o
Non-accelerated filero
Smaller reporting companyoEmerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). oYes þNo
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 24,510,076 shares of Common Stock, par value $0.001 per share, were outstanding at October 28, 2024.

Proto Labs, Inc.
TABLE OF CONTENTS
1
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Proto Labs, Inc.
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
September 30,
2024		December 31,
2023
(Unaudited)
Assets
Current assets
Cash and cash equivalents$87,873 $83,790 
Short-term marketable securities12,638 19,013 
Accounts receivable, net of allowance for doubtful accounts of $2,261 and $2,499 as of September 30, 2024, and December 31, 2023, respectively
69,464 72,848 
Inventory12,415 13,657 
Income taxes receivable665 2,228 
Prepaid expenses and other current assets10,019 9,124 
Total current assets193,074 200,660 
Property and equipment, net237,942 253,655 
Goodwill273,991 273,991 
Other intangible assets, net22,890 25,584 
Long-term marketable securities17,120 8,019 
Operating lease assets3,519 4,628 
Finance lease assets759 960 
Other long-term assets4,491 4,856 
Total assets$753,786 $772,353 
Liabilities and shareholders' equity
Current liabilities  
Accounts payable$15,004 $15,636 
Accrued compensation17,549 15,292 
Accrued liabilities and other18,455 16,872 
Current operating lease liabilities1,450 1,585 
Current finance lease liabilities306 296 
Income taxes payable994 — 
Total current liabilities53,758 49,681 
Long-term operating lease liabilities1,979 3,008 
Long-term finance lease liabilities365 595 
Long-term deferred tax liabilities12,688 18,742 
Other long-term liabilities5,003 5,032 
Total liabilities73,793 77,058 
Shareholders' equity  
Preferred stock, $0.001 par value, authorized 10,000,000 shares; issued and outstanding 0 shares as of each of September 30, 2024, and December 31, 2023
— — 
Common stock, $0.001 par value, authorized 150,000,000 shares; issued and outstanding 24,510,076 and 25,721,957 shares as of September 30, 2024, and December 31, 2023, respectively
25 26 
Additional paid-in capital454,025 466,884 
Retained earnings252,795 256,398 
Accumulated other comprehensive loss(26,852)(28,013)
Total shareholders' equity679,993 695,295 
Total liabilities and shareholders' equity$753,786 $772,353 
The accompanying notes are an integral part of these consolidated financial statements.
2
Proto Labs, Inc.
Consolidated Statements of Comprehensive Income
(In thousands, except share and per share amounts)
(Unaudited)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Statements of Operations:
Revenue$125,619 $130,705 $379,140 $378,829 
Cost of revenue68,389 71,423 207,897 212,648 
Gross profit57,230 59,282 171,243 166,181 
Operating expenses  
Marketing and sales22,619 21,682 69,070 65,863 
Research and development9,772 10,105 31,600 30,647 
General and administrative16,259 17,058 49,167 49,713 
Closure of Japan business— 22 — 186 
Total operating expenses48,650 48,867 149,837 146,409 
Income from operations8,580 10,415 21,406 19,772 
Other income (loss), net1,288 320 3,548 (1,758)
Income before income taxes9,868 10,735 24,954 18,014 
Provision for income taxes2,679 2,781 7,957 7,784 
Net income$7,189 $7,954 $16,997 $10,230 
Net income per share:
Basic$0.29 $0.31 $0.67 $0.39 
Diluted$0.29 $0.31 $0.67 $0.39 
Shares used to compute net income per share:
Basic24,980,53626,023,83025,304,98526,296,304
Diluted25,022,48526,028,45625,382,28026,327,606
Comprehensive Income (net of tax)
Comprehensive income$9,769 $6,887 $18,158 $14,297 
The accompanying notes are an integral part of these consolidated financial statements.
3
Proto Labs, Inc.
Consolidated Statements of Shareholders' Equity
(In thousands, except share amounts)
Common StockAdditional
Paid-In
Capital		Retained
Earnings		Accumulated Other
Comprehensive
Loss		Total
SharesAmount
Balance at December 31, 202325,721,95726 466,884 256,398 (28,013)695,295 
Common shares issued on exercise of options and other, net of shares withheld for tax obligations29,974 — (533)— — (533)
Stock-based compensation expense— — 4,276 — — 4,276 
Repurchases of common stock and other(435,861)— (7,912)(8,252)— (16,164)
 Net income— — — 5,268 — 5,268 
Other comprehensive income
Foreign currency translation adjustment— — — — (925)(925)
Net unrealized gains (losses) on investments in securities— — — — 93 93 
 Comprehensive income    4,436 
Balance at March 31, 202425,316,070$26 $462,715 $253,414 $(28,845)$687,310 
Common shares issued on exercise of options and other, net of shares withheld for tax obligations176,780— 707 — — 707 
Stock-based compensation expense—— 4,244 — — 4,244 
Repurchases of common stock and other(345,234)— (6,266)(4,712)— (10,978)
 Net income—— — 4,540 — 4,540 
Other comprehensive income
Foreign currency translation adjustment—— — — (678)(678)
Net unrealized gains (losses) on investments in securities—— — — 91 91 
 Comprehensive income3,953 
Balance at June 30, 202425,147,616$26 $461,400 $253,242 $(29,432)$685,236 
Common shares issued on exercise of options and other, net of shares withheld for tax obligations—— — — — — 
Stock-based compensation expense——4,196 — — 4,196 
Repurchases of common stock and other(637,540)(1)(11,571)(7,636)— (19,208)
 Net income———7,189 — 7,189 
Other comprehensive income
Foreign currency translation adjustment———— 2,430 2,430 
Net unrealized gains (losses) on investments in securities———— 150 150 
 Comprehensive income9,769 
Balance at September 30, 202424,510,076$25 $454,025 $252,795 $(26,852)$679,993 
Common StockAdditional
Paid-In
Capital		Retained
Earnings		Accumulated Other
Comprehensive
Loss		Total
SharesAmount
Balance at December 31, 202226,888,42527 473,740 258,236 (34,355)697,648 
Common shares issued on exercise of options and other, net of shares withheld for tax obligations26,798— (401)— — (401)
Stock-based compensation expense— — 3,695 — — 3,695 
Repurchases of common stock(712,500)(1)(11,849)(9,475)— (21,325)
 Net income— — — 2,659 — 2,659 
Other comprehensive income
Foreign currency translation adjustment— — — — 527 527 
Net unrealized gains (losses) on investments in securities— — — — 334 334 
 Comprehensive income3,520 
Balance at March 31, 202326,202,723$26 $465,185 $251,420 $(33,494)$683,137 
Common shares issued on exercise of options and other, net of shares withheld for tax obligations169,229— 962 — — 962 
Stock-based compensation expense— — 3,675 — — 3,675 
Repurchases of common stock(276,518)— (4,872)(4,107)— (8,979)
Net loss— — (383)— (383)
Other comprehensive income
Foreign currency translation adjustment— — — — 4,254 4,254 
Net unrealized gains (losses) on investments in securities— — — — 19 19 
 Comprehensive income3,890 
Balance at June 30, 202326,095,434$26 $464,950 $246,930 $(29,221)$682,685 
Common shares issued on exercise of options and other, net of shares withheld for tax obligations1,037— (11)— — (11)
Stock-based compensation expense— — 4,441 — — 4,441 
Repurchases of common stock(310,568)— (5,472)(3,608)— (9,080)
 Net income— — — 7,954 — 7,954 
Other comprehensive income
Foreign currency translation adjustment— — — — (1,307)(1,307)
Net unrealized gains (losses) on investments in securities— — — — 240 240 
 Comprehensive income6,887 
Balance at September 30, 202325,785,903$26 $463,908 $251,276 $(30,288)$684,922 
The accompanying notes are an integral part of these consolidated financial statements.
4
Proto Labs, Inc.
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
Nine Months Ended
September 30,
20242023
Operating activities
Net income$16,997 $10,230 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization26,984 28,213 
Stock-based compensation expense12,716 11,811 
Deferred taxes(6,140)(9,197)
Interest on finance lease obligations26 859 
Loss on impairment of equipment256 — 
Loss on foreign currency translation— 3,906 
Gain on disposal of property and equipment(24)(498)
Other103 122 
Changes in operating assets and liabilities:  
Accounts receivable4,581 (3,058)
Inventories1,321 (150)
Prepaid expenses and other(312)4,127 
Income taxes2,583 4,693 
Accounts payable(2,709)746 
Accrued liabilities and other4,153 4,242 
Net cash provided by operating activities60,535 56,046 
Investing activities
Purchases of property, equipment and other capital assets(8,339)(9,935)
Proceeds from sales of property, equipment and other capital assets34 693 
Purchases of marketable securities(18,087)— 
Proceeds from call redemptions and maturities of marketable securities15,709 19,115 
Net cash (used in) provided by investing activities(10,683)9,873 
Financing activities
Proceeds from exercises of stock options and employee stock purchases2,094 1,986 
Purchases of shares withheld for tax obligations(1,920)(1,436)
Repurchases of common stock(45,958)(39,053)
Principal repayments of finance lease obligations(220)(234)
Net cash used in financing activities(46,004)(38,737)
Effect of exchange rate changes on cash and cash equivalents235 (244)
Net increase in cash and cash equivalents4,083 26,938 
Cash and cash equivalents, beginning of period83,790 56,558 
Cash and cash equivalents, end of period$87,873 $83,496 
The accompanying notes are an integral part of these consolidated financial statements.
5
Notes to Consolidated Financial Statements
Note 1 – Basis of Presentation
The unaudited interim Consolidated Financial Statements of Proto Labs, Inc. (Protolabs, the Company, we, us or our) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying financial statements reflect all adjustments necessary for a fair presentation of the Company’s statements of financial position, results of operations and cash flows for the periods presented. Except as otherwise disclosed herein, these adjustments consist of normal, recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (SEC) on February 16, 2024.
The accompanying Consolidated Balance Sheet as of December 31, 2023 was derived from the audited Consolidated Financial Statements but does not include all disclosures required by U.S. GAAP for a full set of financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K filed on February 16, 2024 as referenced above.
Note 2 – Recent Accounting Pronouncements
The Company did not recently adopt any accounting pronouncements that had a material impact on the Company's Consolidated Financial Statements.
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, that enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The Company is required to adopt this guidance for its annual year ending December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its disclosures.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, that updates reportable segment disclosure requirements primarily through enhanced disclosures about significant expenses and information used to assess segment performance on an annual and interim basis. The Company is required to adopt this guidance for its annual year ending December 31, 2024 and all interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its disclosures.
Note 3 – Net Income per Common Share
Basic net income per share is computed based on the weighted-average number of common shares outstanding. Diluted net income per share is computed based on the weighted-average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. Performance stock units are excluded from the calculation of dilutive potential common shares until the performance conditions have been satisfied. Anti-dilutive options were excluded from the calculation of diluted weighted average shares outstanding and were 466,127 and 393,592 for the three months ended September 30, 2024 and 2023, respectively, and 450,275 and 372,353 for the nine months ended September 30, 2024 and 2023, respectively.
6
The table below sets forth the computation of basic and diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands, except share and per share amounts)2024202320242023
Net income$7,189 $7,954 $16,997 $10,230 
Basic - weighted-average shares outstanding:24,980,53626,023,83025,304,98526,296,304
Effect of dilutive securities:
Employee stock options and other41,9494,62677,29531,302
Diluted - weighted-average shares outstanding:25,022,48526,028,45625,382,28026,327,606
Net income per share:
Basic$0.29 $0.31 $0.67 $0.39 
Diluted$0.29 $0.31 $0.67 $0.39 
Note 4 – Goodwill and Other Intangible Assets
There were no changes in the carrying amount of goodwill during the three and nine months ended September 30, 2024.
Intangible assets other than goodwill at September 30, 2024 and December 31, 2023 were as follows:
September 30, 2024December 31, 2023Useful
Life (in years)		Weighted Average
Useful Life Remaining
(in years)
(in thousands)GrossAccumulated
Amortization		NetGrossAccumulated
Amortization		Net
Intangible assets with finite lives:
Marketing assets$930 $(930)$— $930 $(900)$30 10.00.0
Non-compete agreement837 (688)149 835 (603)232 
2.0 - 5.0
0.9
Software technology13,229 (8,781)4,448 13,229 (7,752)5,477 10.03.3
Software platform26,481 (8,188)18,293 26,373 (6,575)19,798 12.08.3
Tradenames356 (356)— 354 (347)7 3.00.0
Customer relationships12,232 (12,232)— 12,223 (12,183)40 
3.0 - 9.0
0.0
Total intangible assets$54,065 $(31,175)$22,890 $53,944 $(28,360)$25,584 
Intangible assets allocated to the Protolabs Network entities consisted of intangible assets of €11.6 million in Europe and $16.6 million in the United States as of the date of the acquisition. The Euro denominated intangible assets are translated at the end of each period using the current exchange rates resulting in a foreign currency translation adjustment that is recorded as a component of Other Comprehensive Income. Foreign currency unrealized losses related to intangible assets were $1.2 million and $1.3 million as of September 30, 2024 and December 31, 2023, respectively. Amortization expense for intangible assets was $0.9 million and $1.5 million for each of the three months ended September 30, 2024 and 2023, respectively, and $2.8 million and $4.5 million for each of the nine months ended September 30, 2024 and 2023, respectively.
7
Estimated aggregated amortization expense based on the current carrying value of the amortizable intangible assets and current exchange rates is as follows:
(in thousands)Estimated Amortization Expense
Remaining 2024$919
20253,676
20263,574
20273,564
20282,195
Thereafter8,962
Total estimated amortization expense$22,890
Note 5 – Fair Value Measurements
Accounting Standards Codification, Fair Value Measurement (ASC 820), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The Company's assets and liabilities that are required to be measured or disclosed at fair value on a recurring basis include cash and cash equivalents and marketable securities. The Company’s cash consists of bank deposits and cash equivalents consist primarily of money market mutual funds. The Company determines the fair value of these investments using Level 1 inputs. The Company's marketable securities consist of short-term and long-term agency, municipal, corporate and other debt securities. Fair value for the corporate debt securities is primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, U.S. government agency securities, certificates of deposit and U.S. treasury securities are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).
The following table summarizes financial assets as of September 30, 2024 and December 31, 2023 measured at fair value on a recurring basis:
September 30, 2024December 31, 2023
(in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
Financial Assets:
Cash$83,643 $— $— $77,423 $— $— 
Money market mutual fund4,230 $— — 6,367 — — 
Marketable securities20,290 9,468 — 4,482 22,550 — 
Total$108,163 $9,468 $— $88,272 $22,550 $— 
8
Note 6 – Marketable Securities
The Company invests in short-term and long-term agency, municipal, corporate and other debt securities. The securities are categorized as available-for-sale and are recorded at fair value. The following table summarizes information regarding the Company’s short-term and long-term marketable securities as of September 30, 2024 and December 31, 2023:
September 30, 2024
(in thousands)CostUnrealized GainsUnrealized LossesFair Value
U.S. government agency securities$9,817 $— $(72)$9,745 
Corporate debt securities14,242 36 (15)14,263 
U.S. municipal securities5,767 — (17)5,750 
Total marketable securities$29,826 $36 $(104)$29,758 
December 31, 2023
(in thousands)CostUnrealized GainsUnrealized LossesFair Value
U.S. government agency securities$16,798 $— $(278)$16,520 
Corporate debt securities2,511 — (19)2,492 
U.S. municipal securities7,876 — (105)7,771 
Certificates of deposit/time deposits249 — — 249 
Total marketable securities$27,434 $— $(402)$27,032 
Fair values for the corporate debt securities are primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, U.S. government agency securities, certificates of deposit and U.S. treasury securities are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).
Classification of marketable securities as current or non-current is based upon the security’s maturity date as of the date of these financial statements.
The September 30, 2024 balance of available-for-sale debt securities by contractual maturity is shown in the following table at fair value. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
(in thousands)September 30,
2024
Due in one year or less$12,638 
Due after one year through five years17,120 
Total marketable securities$29,758 
Note 7 – Inventory
Inventory consists primarily of raw materials, which are recorded at the lower of cost and net realizable value using the standard cost method, which approximates first-in, first-out (FIFO) cost. The Company periodically reviews its inventory for slow-moving, damaged and discontinued items and provides allowances to reduce such items identified to their recoverable amounts.
9
The Company’s inventory consisted of the following as of the dates indicated:
(in thousands)September 30,
2024		December 31,
2023
Total inventory$13,067 $14,319 
Allowance for obsolescence(652)(662)
Inventory, net of allowance$12,415 $13,657 
Note 8 – Stock-Based Compensation
Under the Amended and Restated Proto Labs Inc. 2022 Long-Term Incentive Plan, the Company has the ability to grant stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, other stock-based awards and cash incentive awards, which was approved by the Company's shareholders at a Special Meeting of Shareholders on August 29, 2022 and was amended and restated by the Company's shareholders at its Annual Meeting of Shareholders on May 23, 2024 (as amended and restated, the 2022 Plan) to increase the number of shares available for issuance pursuant to awards under the 2022 Plan by an additional 430,000 shares, add a minimum vesting requirement, and extend the expiration date so that the term of the 2022 Plan runs for ten years from the date of the shareholder approval. Awards under the 2022 Plan have a maximum term of ten years from the date of grant. The compensation committee may provide that the vesting or payment of any award will be subject to the attainment of specified performance measures in addition to the satisfaction of any continued service requirements and the compensation committee will determine whether such measures have been achieved. The per-share exercise price of stock options and SARs granted under the 2022 Plan generally may not be less than the fair market value of a share of our common stock on the date of the grant.
The Company also has outstanding awards under the 2012 Long-Term Incentive Plan, as amended (the 2012 Plan), although the plan expired in February 2022 and no additional awards have since been or will be made under the 2012 Plan. The 2012 Plan provided the Company the ability to grant stock options, SARs, restricted stock, restricted stock units, other stock-based awards and cash incentive awards. Awards under the 2012 Plan that subsequently expired, were forfeited or cancelled, or settled in cash after August 29, 2022 became available for awards under the 2022 Plan.
Employee Stock Purchase Plan
The Company’s 2012 Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase a variable number of shares of the Company’s common stock each offering period at a discount through payroll deductions of up to 15 percent of their eligible compensation, subject to plan limitations. The ESPP provides for six-month offering periods with a single purchase period ending May 15 and November 15, respectively. At the end of each offering period, employees are able to purchase shares at 85 percent of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period.
Stock-Based Compensation Expense
Stock-based compensation expense was $4.2 million and $4.4 million for the three months ended September 30, 2024 and 2023, respectively, and $12.7 million and $11.8 million for the nine months ended September 30, 2024 and 2023, respectively.
10
Stock Options
The following table summarizes stock option activity during the nine months ended September 30, 2024:
Stock OptionsWeighted-
Average
Exercise Price
Options outstanding at December 31, 2023371,313$59.92 
Granted139,21533.41 
Exercised——
Forfeited(42,220)64.43 
Expired(5,094)67.78 
Options outstanding at September 30, 2024463,214$51.46 
Exercisable at September 30, 2024189,816$70.28 
The outstanding options generally have a term of ten years. For employees, options granted become exercisable ratably over the vesting period, which is generally a period of four years, beginning on the first anniversary of the grant date, subject to the employee’s continuing service to the Company.
The weighted-average grant date fair value of options that were granted during the nine months ended September 30, 2024 was $18.15.
The following table provides the assumptions used in the Black-Scholes pricing model valuation of options during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate
4.28% - 4.30%
3.55% - 4.55%
Expected life (years)
6.25
2.00 - 6.25
Expected volatility
50.62% - 50.72%
49.23% - 55.92%
Expected dividend yield0%0%
As of September 30, 2024, there was $4.3 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.7 years.
Restricted Stock
Restricted stock awards are share-settled awards and restrictions lapse ratably over the vesting period, which is generally a period from three to four years, beginning on the first anniversary of the grant date, subject to the employee's continuing service to the Company. For the board of directors, restrictions generally lapse in full on the first anniversary of the grant date.
11
The following table summarizes restricted stock activity during the nine months ended September 30, 2024:
Restricted
Stock		Weighted-
Average
Grant Date
Fair Value
Per Share
Restricted stock at December 31, 2023653,465$45.89 
Granted336,78533.02 
Restrictions lapsed(191,950)54.48 
Forfeited(51,475)39.06 
Restricted stock at September 30, 2024746,825$38.34 
As of September 30, 2024, there was $20.0 million of unrecognized compensation expense related to non-vested restricted stock, which is expected to be recognized over a weighted-average period of 2.7 years.
Performance Stock
Performance stock units (PSUs) are expressed in terms of a target number of PSUs, with anywhere between 0 percent and 200 percent of that target number capable of being earned and vesting at the end of a three-year performance period depending on the Company’s performance in the final year of the performance period and the award recipient’s continued employment. Certain PSUs granted by the Company in 2021 are based on performance conditions and the related compensation cost is based on the probability that the performance conditions will be achieved. The Company’s PSUs granted in 2022, 2023, 2024 and certain PSUs granted in 2021 are based on market conditions and the related compensation cost is based on the fair value at grant date calculated using a Monte Carlo pricing model.
The following table summarizes performance stock activity during the nine months ended September 30, 2024:
Performance
Stock		Weighted-
Average
Grant Date
Fair Value
Per Share
Performance stock at December 31, 2023107,097$74.08 
Granted79,43648.20 
Restrictions lapsed——
Performance change(2,772)227.14 
Forfeited——
Performance stock at September 30, 2024183,761$60.58 
12
The following table provides the assumptions used in the Monte Carlo pricing model valuation of PSUs during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate4.37%4.35%
Expected life (years)2.882.88
Expected volatility51.40%
58.00%
Expected dividend yield0%0%
As of September 30, 2024, there was $5.3 million of unrecognized compensation expense related to non-vested performance stock, which is expected to be recognized over a weighted-average period of 1.9 years.
Employee Stock Purchase Plan
The following table presents the assumptions used to estimate the fair value of the ESPP during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate
5.07% - 5.16%
4.60% - 4.82%
Expected life (months)6.006.00
Expected volatility
30.97% - 47.92%
47.38% - 67.84%
Expected dividend yield0%0%
13
Note 9 – Accumulated Other Comprehensive Income (Loss)
Other comprehensive income (loss) is comprised of foreign currency translation adjustments and net unrealized gains (losses) on investments in securities.
The following table presents the changes in accumulated other comprehensive income (loss) balances during the three and nine months ended September 30, 2024 and 2023:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Balance at beginning of period$(29,432)$(29,221)$(28,013)$(34,355)
Foreign currency translation adjustments
Other comprehensive income (loss) before reclassifications2,430 (1,307)827 (432)
Amounts reclassified from accumulated other comprehensive loss— — — 3,906 
Net current-period other comprehensive income (loss)2,430 (1,307)827 3,474 
Net unrealized gains (loss) on investments in securities
Other comprehensive income before reclassifications150 240 334 593 
Amounts reclassified from accumulated other comprehensive loss— — — — 
Net current-period other comprehensive income150 240 334 593 
Balance at end of period$(26,852)$(30,288)$(26,852)$(30,288)
Note 10 – Income Taxes
The Company is subject to income tax in multiple jurisdictions and the use of estimates is required to determine the provision for income taxes. For the three months ended September 30, 2024 and 2023, the Company recorded an income tax provision of $2.7 million and $2.8 million, respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded an income tax provision of $8.0 million and $7.8 million, respectively. The income tax provision is based on the estimated annual effective tax rate for the year applied to pre-tax income. The effective income tax rate for the three months ended September 30, 2024 was 27.1 percent compared to 25.9 percent in the same period of the prior year. The effective tax rate increased by 1.2 percent for the three months ended September 30, 2024 when compared to the same period in 2023, primarily due to a reduction in expenditures that qualify for the research and development credit. The effective income tax rate for the nine months ended September 30, 2024 was 31.9 percent compared to 43.2 percent in the same period of the prior year. The effective tax rate decreased by 11.3 percent for the nine months ended September 30, 2024 when compared to the same period in 2023, primarily due to the prior year one-time tax impact of the foreign currency translation loss from the closure of our Japan business.
The effective income tax rate for the three and nine months ended September 30, 2024 differs from the U.S. federal statutory rate of 21.0 percent due to various factors, including operating in multiple state and foreign jurisdictions partially offset by tax credits for which the Company qualifies.
The Company had unrecognized tax benefits totaling $3.7 million as of September 30, 2024 and $3.6 million as of December 31, 2023, respectively, that if recognized would result in a reduction of the Company’s effective tax rate. The liabilities are classified as other long-term liabilities in the accompanying consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters in income tax expense and reports the liability in current or long-term income taxes payable as appropriate.
14
Note 11 – Segment Reporting
The Company’s reportable segments are based on the internal reporting used by the Company’s Chief Executive Officer, who is the chief operating decision maker (CODM), to assess operating performance and make decisions about the allocation of resources. The Corporate Unallocated and Japan category includes non-reportable segments, as well as research and development and general and administrative costs, that the Company does not allocate directly to its operating segments.
Intercompany transactions primarily relate to intercontinental activity and have been eliminated and are excluded from the reported amounts. The difference between income from operations and pre-tax income relates to foreign currency-related gains and losses and interest income on cash balances and investments, which are not allocated to business segments.
Revenue and income from operations by reportable segment for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(dollars in thousands)2024202320242023
Revenue:
United States$99,571 $103,940 $299,593 $298,007 
Europe26,048 26,765 79,547 80,822 
Total revenue$125,619 $130,705 $379,140 $378,829 
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Income (Loss) from Operations:
United States$25,687 $27,178 $76,260 $69,713 
Europe(2,398)(3,006)(6,574)(8,870)
Corporate Unallocated and Japan(14,709)(13,757)(48,280)(41,071)
Total Income from Operations$8,580 $10,415 $21,406 $19,772 
Total long-lived assets at September 30, 2024 and December 31, 2023 were as follows:
(in thousands)September 30,
2024		December 31,
2023
Total long-lived assets:
United States$187,130 $201,388 
Europe50,812 52,267 
Total Long-lived Assets$237,942 $253,655 
15
Revenue by product line for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(dollars in thousands)2024202320242023
Revenue:
Injection Molding$46,831 $51,688 $148,574 $152,455 
CNC Machining53,327 52,916 154,498 149,317 
3D Printing21,437 21,622 64,300 63,952 
Sheet Metal3,743 4,291 11,218 12,478 
Other Revenue281 188 550 627 
Total Revenue$125,619 $130,705 $379,140 $378,829 
Note 12 – Subsequent Event
On October 21, 2024, the Board of Directors of Proto Labs, Inc. approved a plan related to the Company's manufacturing facilities in Germany. The plan includes the closure of the Company's prototype injection molding manufacturing facility in Eschenlohe, Germany, and the discontinuation of Direct Metal Laser Sintering 3D printing services through its Putzbrunn, Germany, 3D printing facility. Affected employees in Germany will receive severance and other transition assistance that meet or exceed local requirements. The Company expects to substantially complete the plan within the next year.
The Company will continue offering all its manufacturing services to customers across Europe, including injection molding and metal 3D printing. These services will be fulfilled through internal manufacturing facilities and a network of manufacturing partners, consistent with the Company's recently announced global operations organization.

The approved plan is expected to lead to total restructuring charges in the range of $4.5 million to $6.0 million consisting of approximately $2.5 million to $3.5 million in severance and other employee-related costs, and $2.0 million to $2.5 million in fixed asset and facility related write-down expenses. The company expects to incur approximately $4.0 million of the total restructuring charge in the fourth quarter of 2024, with the remaining charge to be incurred throughout the remainder of the restructuring process.

The total cash expenditures associated with the plan are expected to be in the range of $3.0 million to $4.0 million, consisting primarily of severance and other employee related costs.
16
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2023.
Forward-Looking Statements
Statements contained in this report regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other factors that may cause our results to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in Item 1A. “Risk Factors” of this Form 10-Q, as well as our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC). Other unknown or unpredictable factors also could have material adverse effects on our future results. We cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, we expressly disclaim any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
Overview
We are one of the world’s largest, fastest and most comprehensive digital manufacturers of custom parts. Our vision is accelerating innovation by revolutionizing manufacturing. Our mission is to empower companies to bring new ideas to market by offering the fastest and most comprehensive digital manufacturing service in the world. We accomplish this by offering a variety of manufacturing capabilities fulfilled through a combination of owned manufacturing factories and a worldwide network of premium manufacturing partners. Our automated quoting and manufacturing systems are highly integrated with our manufacturing and fulfillment systems, which allow us to offer a vast array of manufacturing technologies in a variety of materials across a continuum of lead times and prices. Our technology-enabled digital engineering and manufacturing applications enable us to produce commercial-grade plastic, metal, and liquid silicone rubber parts in as fast as one day. We utilize injection molding, computer numerical control (CNC) machining, 3D printing and sheet metal fabrication to manufacture custom parts for our customers.
Our customers conduct nearly all of their business with us over the Internet. We target our products to the millions of product developers and engineers who use three-dimensional computer-aided design (3D CAD) software to design products across a diverse range of end-markets, to the procurement and supply chain professionals seeking to easily and efficiently source custom parts, and to a wide variety of customers seeking to purchase custom made parts. We believe our use of advanced technology enables us to offer significant advantages at competitive prices to many customers and is the primary reason we have become a leading supplier of custom parts.
We have established our operations in the United States and Europe. Our primary manufacturing product lines currently include Injection Molding, CNC Machining, 3D Printing and Sheet Metal. We continually seek to expand the range of sizes and geometric complexity of the parts we can make with these processes, to extend the variety of materials we are able to support, and to identify additional manufacturing processes to which we can apply our technology or incorporate into our manufacturing network in order to better serve the evolving preferences and needs of our customers. With the addition of the Protolabs Network in 2021, our global network of premium manufacturing partners significantly expands the breadth and depth of our manufacturing capabilities, enabling us to offer customers a wider variety of lead times and pricing options, and an expanded envelope of parts (complexity, size, etc.).
Key Financial Measures and Trends
Revenue
Our operations are comprised of two geographic operating segments in the United States and Europe. On May 27, 2022, the Company's board of directors approved a plan for the closure of our manufacturing facility in Japan and announced an intention to cease operations in the region. The Company dissolved its Japan operations in December 2023. Revenue is derived from our Injection Molding, CNC Machining, 3D Printing and Sheet Metal product lines. Injection Molding revenue consists of sales of custom injection molds and injection-molded parts. CNC Machining revenue consists of sales of CNC-machined custom parts. 3D Printing revenue consists of sales of 3D-printed parts. Sheet Metal revenue consists of
17
sales of fabricated sheet metal custom parts. Our revenue is generated from a diverse customer base and our historical and current efforts to increase revenue have been directed at gaining new customers and selling to our existing customer base by increasing marketing and selling activities, including:
•expanding the breadth and scope of our products by adding more sizes and materials to our offerings;
•the introduction of our 3D Printing product line through our acquisition of FineLine in 2014;
•expanding 3D Printing to Europe through our acquisition of Alphaform in 2015;
•the introduction of our Sheet Metal product line through our acquisition of Rapid Manufacturing Group, LLC in 2017;
•continuously improving the usability of our product lines such as our web-centric applications; and
•providing customers with on-demand access to a global network of premium manufacturing partners through our acquisition of Hubs in 2021.
Cost of Revenue, Gross Profit and Gross Margin
Cost of revenue consists primarily of raw materials, costs to procure parts through our network of premium manufacturing partners, equipment depreciation, employee compensation including benefits and stock-based compensation, facilities costs and overhead allocations associated with the manufacturing process for molds and customer parts. We expect our personnel-related costs to increase in order to retain and attract top talent and remain competitive in the market. Overall, we expect cost of revenue to increase in absolute dollars.
We define gross profit as our revenue less our cost of revenue, and we define gross margin as gross profit expressed as a percentage of revenue. Our gross profit and gross margin are affected by many factors, including our mix of revenue by product line, pricing, sales volume, manufacturing costs, the costs associated with increasing production capacity, the mix between domestic and foreign revenue sources, the mix between revenue produced in our internal manufacturing operations and outsourced to our external manufacturing partners, and foreign currency exchange rates.
Operating Expenses
Operating expenses consist of marketing and sales, research and development and general and administrative expenses. Personnel-related costs are the most significant component in each of these categories.
Our business strategy is to continue to be a leading online and technology-enabled manufacturer of quick-turn, on-demand injection-molded, CNC-machined, 3D-printed and fabricated sheet metal custom parts for prototyping and low-volume production. In order to achieve our goals, we anticipate continued substantial investments in technology and personnel, resulting in increased operating expenses in the future.
Marketing and sales. Marketing and sales expense consists primarily of employee compensation, benefits, commissions, stock-based compensation, marketing demand generation costs such as electronic, print and pay-per-click advertising, trade shows and other related overhead. We expect sales and marketing expense to increase in the future as we increase the number of marketing and sales professionals and marketing demand generation costs targeted to increase our customer base and grow revenue.
Research and development. Research and development expense consists primarily of personnel and outside service costs related to the development of new processes and product lines, enhancement of existing product lines, development of software for internal use, maintenance of internally developed software, quality assurance and testing. Costs for internal use software are evaluated by project and capitalized where appropriate under ASC 350-40, Intangibles — Goodwill and Other, Internal-Use Software. We expect research and development expense to increase in the future as we seek to enhance our e-commerce interface technology, internal software and supporting business systems, and continue to expand our product lines.
General and administrative. General and administrative expense consists primarily of employee compensation, benefits, stock-based compensation, professional service fees related to accounting, tax and legal, and other related overhead. We expect general and administrative expense to increase in the future as we continue to grow and expand as a global organization.
18
Closure of Japan business. Closure of Japan business expense is driven by our decision to close the Japan manufacturing facility and exit the Japan market. The expenses consist primarily of professional service costs.
Other Income, net
Other income, net primarily consists of foreign currency-related gains and losses and interest income on cash balances and investments. Our foreign currency-related gains and losses will vary depending upon movements in underlying foreign currency exchange rates. Our interest income will vary each reporting period depending on our average cash balances during the period, composition of our marketable security portfolio and the current level of interest rates.
Provision for Income Taxes
Provision for income taxes is comprised of federal, state, local and foreign taxes based on pre-tax income. Overall, our effective tax rate for 2024 and beyond may differ from historical effective tax rates due to increases in losses in foreign operations that are not eligible for tax benefits on account of valuation allowances, as well as any future tax law changes that may impact our effective tax rate.
Results of Operations
The following table summarizes our results of operations and the related changes for the periods indicated. The results below are not necessarily indicative of the results for future periods.
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
(dollars in thousands)20242023$%20242023$%
Revenue$125,619 100.0 $130,705 100.0 $(5,086)(3.9)$379,140 100.0 $378,829 100.0 $311 0.1 
Cost of revenue68,389 54.4 71,423 54.6 (3,034)(4.2)207,897 54.8 212,648 56.1 (4,751)(2.2)
Gross profit57,230 45.6 59,282 45.4 (2,052)(3.5)171,243 45.2 166,181 43.9 5,062 3.0 
Operating expenses
Marketing and sales22,619 18.0 21,682 16.6 937 4.3 69,070 18.2 65,863 17.4 3,207 4.9 
Research and development9,772 7.8 10,105 7.7 (333)(3.3)31,600 8.3 30,647 8.1 953 3.1 
General and administrative16,259 12.9 17,058 13.1 (799)(4.7)49,167 13.0 49,713 13.1 (546)(1.1)
Closure of Japan business— — 22 — (22)(100.0)— — 186 — (186)(100.0)
Total operating expenses48,650 38.7 48,867 37.4 (217)(0.4)149,837 39.5 146,409 38.6 3,428 2.3 
Income from operations8,580 6.8 10,415 8.0 (1,835)(17.6)21,406 5.6 19,772 5.2 1,634 8.3 
Other income (loss), net1,288 1.0 320 0.2 968 302.5 3,548 0.9 (1,758)(0.5)5,306 301.8 
Income before income taxes9,868 7.9 10,735 8.2 (867)(8.1)24,954 6.6 18,014 4.8 6,940 38.5 
Provision for income taxes2,679 2.1 2,781 2.1 (102)(3.7)7,957 2.1 7,784 2.1 173 2.2 
Net income$7,189 5.7 %$7,954 6.1 %$(765)(9.6)%$16,997 4.5 %$10,230 2.7 %$6,767 66.1 %
19
Stock-based compensation expense included in the statements of operations data above for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(dollars in thousands)2024202320242023
Stock options, restricted stock and performance stock$3,906 $4,118 $11,799 $10,706 
Employee stock purchase plan290 323 917 1,105 
Total stock-based compensation expense$4,196 $4,441 $12,716 $11,811 
Cost of revenue$474 $462 $1,401 $1,388 
Operating expenses:
Marketing and sales727 962 2,378 2,510 
Research and development671 674 2,031 1,887 
General and administrative2,324 2,343 6,906 6,026 
Total stock-based compensation expense$4,196 $4,441 $12,716 $11,811 
Comparison of Three Months Ended September 30, 2024 and 2023
Revenue
Revenue by reportable segment and the related changes for the three months ended September 30, 2024 and 2023 were as follows:
Three Months Ended September 30,
20242023Change
(dollars in thousands)$% of Total Revenue$% of Total Revenue$%
Revenue:
United States$99,571 79.3 %$103,940 79.5 %$(4,369)(4.2)%
Europe26,048 20.7 %26,765 20.5 %(717)(2.7)
Total revenue$125,619 100.0 %$130,705 100.0 %$(5,086)(3.9 %)
Our revenue decreased $5.1 million, or 3.9%, for the three months ended September 30, 2024 compared to the same period in 2023. The decline in revenue was primarily driven by a decrease in larger quantity part orders, which were particularly strong in the three months ended September 30, 2023. By reportable segment, revenue in the United States decreased $4.4 million, or 4.2%, for the three months ended September 30, 2024 compared to the same period in 2023. Revenue in Europe decreased $0.7 million, or 2.7%, for the three months ended September 30, 2024 compared to the same period in 2023. Revenue generated from the Protolabs Network was $25.3 million and $22.6 million for the three months ended September 30, 2024 and 2023, respectively. International revenue was positively impacted by $0.5 million during the three months ended September 30, 2024 compared to the same period in 2023 as a result of foreign currency movements, primarily due to the strengthening of the British Pound and Euro relative to the United States Dollar.
During the three months ended September 30, 2024, we served 22,511 unique customer contacts, which is a decrease of 2.5% from the same period in 2023. Our customer contacts served decreased at a rate less than our decrease in revenue. This was primarily due to our mix of customers served in the quarter as compared to the same period in 2023 and our strategic focus to earn larger orders from our customers as we strive to be their supplier of choice by serving their custom parts needs through the comprehensive offer of our factory and the Protolabs Network.
20
Revenue by product line and the related changes for the three months ended September 30, 2024 and 2023 were as follows:
Three Months Ended September 30,
20242023Change
(dollars in thousands)$% of Total Revenue$% of Total Revenue$%
Revenue:
Injection Molding$46,831 37.3 %$51,688 39.6 %$(4,857)(9.4)%
CNC Machining53,327 42.4 52,916 40.5 411 0.8 
3D Printing21,437 17.1 21,622 16.5 (185)(0.9)
Sheet Metal3,743 3.0 4,291 3.3 (548)(12.8)
Other Revenue281 0.2 188 0.1 93 49.5 
Total Revenue$125,619 100.0 %$130,705 100.0 %$(5,086)(3.9)%
By product line, our revenue decrease was driven by a 9.4% decrease in Injection Molding revenue, a 12.8% decrease in Sheet Metal revenue and a 0.9% decrease in 3D Printing revenue, which was partially offset by a 0.8% increase in CNC Machining revenue and a 49.5% increase in Other Revenue, in each case for the three months ended September 30, 2024 compared to the same period in 2023.
Cost of Revenue, Gross Profit and Gross Margin
Cost of Revenue. Cost of revenue decreased $3.0 million, or 4.2%, for the three months ended September 30, 2024 compared to the same period in 2023, while revenue decreased 3.9% for the three months ended September 30, 2024 compared to the same period in 2023. The decrease in the cost of revenue of $3.0 million was primarily driven by lower revenue volumes in our factory business, which resulted in decreases of $1.6 million in raw materials and production costs, and $1.4 million in personnel and related costs as we aligned staffing to order volumes during the three months ended September 30, 2024 compared to the same period in 2023. The cost reductions in our digital manufacturing factory business were primarily the result of focused management of resources aligned to order volumes, partially supported by increased automation.
Gross Profit and Gross Margin. Gross profit decreased from $59.3 million in the three months ended September 30, 2023 to $57.2 million in the three months ended September 30, 2024. Gross margin increased from 45.4% in the three months ended September 30, 2023 to 45.6% in the three months ended September 30, 2024.
Operating Expenses, Other (Loss) Income, net and Provision for Income Taxes
Marketing and Sales. Marketing and sales expenses increased $0.9 million, or 4.3%, during the three months ended September 30, 2024 compared to the same period in 2023. The increase in marketing and sales expenses was primarily driven by marketing demand generation costs increases of $0.4 million, other operating cost increases of $0.3 million and increases in personnel and related costs of $0.2 million due to additional headcount, partially offset by lower incentive compensation during the three months ended September 30, 2024 when compared to the same period in 2023.
Research and Development. Our research and development expenses decreased $0.3 million, or 3.3%, during the three months ended September 30, 2024 compared to the same period in 2023 primarily due to decreases in personnel and related costs of $0.9 million primarily due to lower incentive compensation, partially offset by increases of $0.4 million of other operating costs and $0.2 million in professional services .
General and Administrative. Our general and administrative expenses decreased $0.8 million, or 4.7%, during the three months ended September 30, 2024 compared to the same period in 2023 primarily due to the three months ended September 30, 2023 including a $0.5 million reserve for specific receivables deemed to be uncollectible. Also contributing to the decrease during the three months ended September 30, 2024 compared to the same period in 2023 were decreases of $0.7 million in operating costs and $0.4 million in intangible amortization expense, partially offset by increases of $0.6 million in personnel and related costs and $0.2 million in professional services and other costs.
21
Closure of Japan business. We had no expenses related to the closure of our Japan business during the three months ended September 30, 2024. Our decision to close our Japan business resulted in less than $0.1 million in professional services expenses during the three months ended September 30, 2023.
Other income, net. We recognized other income, net of $1.3 million for the three months ended September 30, 2024, an increase of $1.0 million compared to other income, net of $0.3 million for the three months ended September 30, 2023. Other income, net for the three months ended September 30, 2024 primarily consisted of $1.3 million in interest income on investments and other income. Other income, net for the three months ended September 30, 2023 primarily consisted of $0.5 million in interest income on investments and other income, partially offset by $0.2 million of foreign currency losses.
Provision for Income Taxes. Our effective tax rate of 27.1% for the three months ended September 30, 2024 increased 1.2% compared to 25.9% for the same period in 2023. The increase in the effective tax rate was primarily due to a reduction in expenditures that qualify for the research and development credit. Our income tax provision of $2.7 million for the three months ended September 30, 2024 decreased $0.1 million as compared to our income tax provision of $2.8 million for the same period in 2023.
Comparison of Nine Months Ended September 30, 2024 and 2023
Revenue
Revenue by reportable segment and the related changes for the nine months ended September 30, 2024 and 2023 were as follows:
Nine Months Ended September 30,
20242023Change
(dollars in thousands)$% of Total Revenue$% of Total Revenue$%
Revenue:
United States$299,593 79.0 %$298,007 78.7 %$1,586 0.5 %
Europe79,547 21.0 %80,822 21.3 %(1,275)(1.6)
Total revenue$379,140 100.0 %$378,829 100.0 %$311 0.1 %
Our revenue increased $0.3 million, or 0.1%, for the nine months ended September 30, 2024 compared to the same period in 2023. By reportable segment, revenue in the United States increased $1.6 million, or 0.5%, for the nine months ended September 30, 2024 compared to the same period in 2023. Revenue in Europe decreased $1.3 million, or 1.6%, for the nine months ended September 30, 2024 compared to the same period in 2023. Revenue generated from Protolabs Network was $73.9 million and $60.1 million for the nine months ended September 30, 2024 and 2023, respectively. International revenue was positively impacted by $1.4 million during the nine months ended September 30, 2024 compared to the same period in 2023 as a result of foreign currency movements, primarily due to the strengthening of the British Pound and Euro relative to the United States Dollar.
During the nine months ended September 30, 2024, we served 43,671 unique product developers and engineers, a decrease of 4.4% from the same period in 2023. Our customer contacts served decreased compared to an increase in revenue. This was primarily due to our strategic focus to earn larger orders from our customers as we strive to be their supplier of choice by serving their custom parts needs through the comprehensive offer of our factory and the Protolabs Network.
22
Revenue by product line and the related changes for the nine months ended September 30, 2024 and 2023 were as follows:
Nine Months Ended September 30,
20242023Change
(dollars in thousands)$% of Total Revenue$% of Total Revenue$%
Revenue:
Injection Molding$148,574 39.2 %$152,455 40.2 %$(3,881)(2.5)%
CNC Machining154,498 40.7 149,317 39.4 5,181 3.5 
3D Printing64,300 17.0 63,952 16.9 348 0.5 
Sheet Metal11,218 3.0 12,478 3.3 (1,260)(10.1)
Other Revenue550 0.1 627 0.2 (77)(12.3)
Total Revenue$379,140 100.0 %$378,829 100.0 %$311 0.1 %
By product line, our revenue increase was driven by a 3.5% increase in CNC Machining revenue and a 0.5% increase in 3D Printing revenue, which was partially offset by a 2.5% decrease in Injection Molding revenue, a 10.1% decrease in Sheet Metal revenue and a 12.3% decrease in Other Revenue in each case for the nine months ended September 30, 2024 compared to the same period in 2023.
Cost of Revenue, Gross Profit and Gross Margin
Cost of Revenue. Cost of revenue decreased $4.8 million, or 2.2%, for the nine months ended September 30, 2024 compared to the same period in 2023, while revenue increased 0.1% for the nine months ended September 30, 2024 compared to the same period in 2023. The decrease in cost of revenue of $4.8 million was driven by reductions in headcount and overtime leading to lower personnel and related costs of $3.8 million primarily in our digital manufacturing factory business during the nine months ended September 30, 2024 compared to the same period in 2023. The cost reductions in our digital manufacturing factory business were the result of focused management of resources aligned to order volumes, partially supported by increased automation. Also contributing to the decrease in cost of revenue during the nine months ended September 30, 2024 compared to the same period in 2023 were decreases in order volumes fulfilled through our factories as customer orders fulfilled through our network increased. This resulted in a reduction in raw materials and production costs of $1.9 million, which were partially offset by increases in equipment and facility-related costs of $0.9 million.
Gross Profit and Gross Margin. Gross profit increased from $166.2 million in the nine months ended September 30, 2023 to $171.2 million in the nine months ended September 30, 2024. Gross margin increased from 43.9% in the nine months ended September 30, 2023 to 45.2% in the nine months ended September 30, 2024.
Operating Expenses, Other Income (Loss), net and Provision for Income Taxes
Marketing and Sales. Marketing and sales expenses increased $3.2 million, or 4.9%, during the nine months ended September 30, 2024 compared to the same period in 2023. The increase was driven by increases in personnel and related costs of $1.4 million, marketing demand generation costs increases of $1.1 million and other operating costs increases of $0.7 million during the nine months ended September 30, 2024 when compared to the same period in 2023.
Research and Development. Our research and development expenses increased $1.0 million, or 3.1%, during the nine months ended September 30, 2024 compared to the same period in 2023 primarily due to increases of $0.9 million in other operating costs, $0.4 million in professional services and $0.2 million in administrative costs, partially offset by decreases in personnel and related costs of $0.5 million primarily due to lower incentive compensation.
General and Administrative. Our general and administrative expenses decreased $0.5 million, or 1.1%, during the nine months ended September 30, 2024 compared to the same period in 2023 primarily due to decreases in intangible amortization costs of $1.1 million, other operating costs of $0.9 million and administrative costs of $0.9 million, partially offset by increases in personnel and related costs of $1.5 million, in stock-based compensation of $0.8 million and in professional services of $0.7 million. In addition, the nine months ended September 30, 2023 included a $0.5 million reserve for specific receivables deemed to be uncollectible.
23
Closure of Japan business. We had no expenses related to the closure of our Japan business during the nine months ended September 30, 2024. During the nine months ended September 30, 2023, we recognized $0.2 million in professional services expenses related to the closure.
Other income (loss), net. We recognized other income, net of $3.5 million for the nine months ended September 30, 2024, an increase of $5.3 million compared to other loss, net of $1.8 million for the nine months ended September 30, 2023. Other income, net for the nine months ended September 30, 2024 primarily consisted of $3.9 million in interest income on investments and other income, partially offset by $0.4 million of foreign currency losses. Other loss, net for the nine months ended September 30, 2023 primarily consisted of a $3.9 million foreign currency translation loss from the substantial completion on the closure of our Japan business, which was partially offset by $2.1 million in interest income on investments and other income.
Provision for Income Taxes. Our effective tax rate of 31.9% for the nine months ended September 30, 2024 decreased 11.3% compared to 43.2% for the same period in 2023. The decrease in the effective tax rate was primarily due to the prior year one-time tax impact of the foreign currency translation loss from the substantial completion on the closure of our Japan business. Our income tax provision of $8.0 million for the nine months ended September 30, 2024 increased $0.2 million compared to our income tax provision of $7.8 million for the nine months ended September 30, 2023.
Liquidity and Capital Resources
Cash Flows
The following table summarizes our cash flows during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
(dollars in thousands)20242023
Net cash provided by operating activities$60,535 $56,046 
Net cash (used in) provided by investing activities(10,683)9,873 
Net cash used in financing activities(46,004)(38,737)
Effect of exchange rate changes on cash and cash equivalents235 (244)
Net increase in cash and cash equivalents$4,083 $26,938 
Sources of Liquidity
Historically, we have primarily financed our operations and capital expenditures through cash flow from operations. We had cash and cash equivalents of $87.9 million as of September 30, 2024, an increase of $4.1 million from December 31, 2023. The increase in our cash was primarily due to cash provided by operating activities of $60.5 million and proceeds from call redemptions and maturities of marketable securities of $15.7 million, which were partially offset by $8.3 million for purchases of property, equipment and other capital assets, $18.1 million for purchases of marketable securities and $46.0 million in repurchases of common stock.
We believe that our existing cash and cash equivalents together with cash generated from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months.
Cash Flows from Operating Activities
Cash flows from operating activities were $60.5 million during the nine months ended September 30, 2024 and primarily consisted of net income of $17.0 million, adjusted for certain non-cash items, including depreciation and amortization of $27.0 million, stock-based compensation expense of $12.7 million, changes in operating assets and liabilities and other items totaling $9.6 million and a non-cash impairment of equipment of $0.3 million, which were partially offset by deferred taxes of $6.1 million. Cash flows from operating activities were $56.0 million during the nine months ended September 30, 2023 and primarily consisted of net income of $10.2 million, adjusted for certain non-cash items, including depreciation and amortization of $28.2 million, stock-based compensation expense of $11.8 million, foreign currency translation loss of $3.9 million, interest on finance lease obligations of $0.9 million and changes in operating assets and liabilities and other items totaling $10.6 million, which were partially offset by deferred taxes of $9.2 million and a gain on the disposal of property and equipment of $0.5 million.
24
Cash flows from operating activities increased $4.5 million during the nine months ended September 30, 2024 compared to the same period in 2023, primarily due to increases in net income of $6.8 million, deferred taxes of $3.1 million, stock-based compensation of $0.9 million and other non-cash property and equipment adjustments of $0.7 million, which were partially offset by decreases in depreciation and amortization of $1.2 million, changes in operating assets and liabilities totaling $1.0 million, and interest on finance lease obligations of $0.8 million. The nine months ended September 30, 2023 also included a $3.9 million non-cash foreign currency loss.
Cash Flows from Investing Activities
Cash used in investing activities was $10.7 million during the nine months ended September 30, 2024, consisting of $8.3 million for net purchases of property, equipment and other capital assets and $2.4 million of purchases of marketable securities, net of proceeds from call redemptions and maturities.
Cash provided by investing activities was $9.9 million during the nine months ended September 30, 2023, consisting of $19.1 million in proceeds from call redemptions and maturities of marketable securities, which were partially offset by $9.2 million for net purchases of property, equipment and other capital assets.
Cash Flows from Financing Activities
Cash used in financing activities was $46.0 million during the nine months ended September 30, 2024, consisting of $46.0 million in repurchases of common stock, $1.9 million in purchases of shares withheld for tax obligations associated with equity transactions and $0.2 million for repayments of finance lease obligations, which were partially offset by $2.1 million in proceeds from purchases of shares under the Employee Stock Purchase Plan.
Cash used in financing activities was $38.7 million during the nine months ended September 30, 2023, consisting of $39.1 million in repurchases of common stock, $1.4 million in purchases of shares withheld for tax obligations associated with equity transactions and $0.2 million for repayments of finance lease obligations, which were partially offset by $2.0 million in proceeds from purchases of shares under the Employee Stock Purchase Plan.
Critical Accounting Estimates
We have adopted various accounting policies to prepare the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these financial statements requires us to make estimates, judgements and assumptions. Our significant accounting policies and estimates are disclosed in Note 2 to the Consolidated Financial Statements included Part II, Item 8 in our Annual Report on Form 10-K for the year ended December 31, 2023. There were no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2024.
Recent Accounting Pronouncements
For information on recent accounting pronouncements, see Note 2 to the Consolidated Financial Statements appearing in Part I, Item 1 in this Quarterly Report on Form 10-Q.
25
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Foreign Currency Risk
As a result of our foreign operations, we have revenue, expenses, assets and liabilities that are denominated in foreign currencies. We generate revenue and incur production and sourcing costs and operating expenses in British Pounds and Euros.
Our operating results and cash flows are adversely impacted when the United States Dollar appreciates relative to foreign currencies. Additionally, our operating results and cash flows are adversely impacted when the British Pound appreciates relative to the Euro. As we expand internationally, our results of operations and cash flows will become increasingly subject to changes in foreign currency exchange rates.
We have not used forward contracts or currency borrowings to hedge our exposure to foreign currency risk. Foreign currency risk can be assessed by estimating the change in results of operations or financial position resulting from a hypothetical 10% adverse change in foreign exchange rates. We believe such a change would generally not have a material impact on our financial position, but could have a material impact on our results of operations. During the nine months ended September 30, 2023, we recognized a foreign currency translation loss of $3.9 million in connection with substantially completing our closure of our Japan business. We recognized foreign currency losses of $0.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively. We recognized foreign currency losses of $0.4 million and $0.1 million during the nine months ended September 30, 2024 and 2023, respectively. The changes in foreign exchange rates had a positive impact on consolidated revenue of $0.5 million for the three months ended September 30, 2024 and a positive impact on consolidated revenue of $1.4 million as for the nine months ended September 30, 2024 compared to the same period in 2023.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (Exchange Act)) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures are effective and provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported accurately and within the time frames specified in the SEC’s rules and forms and accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
26
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of these financial statements, we do not believe we are party to any litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business.
Item 1A. Risk Factors
Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 includes a discussion of our risk factors. There have been no material changes from the risk factors described in our Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On February 7, 2023 our board of directors approved a new stock repurchase program that added $50 million to our previous stock repurchase authorization, which increased the total stock repurchase authorized to $250 million. We have $42.5 million remaining under this authorization. The timing and amount of any share repurchases will be determined by our management based on market conditions and other factors.
During the three months ended September 30, 2024, we repurchased 637,540 shares of our common stock at a total purchase price of $19.0 million under this program. Common stock repurchase activity through September 30, 2024 was as follows:
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as
Part of Publicly Announced Plans or
Programs		Maximum Dollar Value of Shares that
May Yet Be Purchased Under the Plans
or Programs (in thousands) (1)
July 1, 2024 through July 31, 2024—$— —$61,449 
August 1, 2024 through August 31, 2024441,514$30.12 441,514$48,150 
September 1, 2024 through September 30, 2024196,026$29.08 196,026$42,450 
637,540$29.80 637,540$42,450 
Item 3. Defaults Upon Senior Securities
No matters to disclose.
Item 4. Mine Safety Disclosures
No matters to disclose.
Item 5. Other Information
During the three months ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
27
Item 6. Exhibits
The following documents are filed as part of this report:
Exhibit NumberDescription of Exhibit
3.1
3.2
3.3
31.1
31.2
32.1
101.INSInline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)*
101.SCHInline XBRL Taxonomy Extension Schema Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
*Filed herewith.
28
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Proto Labs, Inc.
Date: November 7, 2024
/s/ Robert Bodor
Robert Bodor
President and Chief Executive Officer
(Principal Executive Officer)
Date: November 7, 2024
/s/ Daniel Schumacher
Daniel Schumacher
Chief Financial Officer
(Principal Financial Officer)
29

Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Robert Bodor, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Proto Labs, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 7, 2024
By:/s/ Robert Bodor
Robert Bodor
President and Chief Executive Officer
(Principal Executive Officer)


Exhibit 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Daniel Schumacher, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Proto Labs, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 7, 2024
By:/s/ Daniel Schumacher
Daniel Schumacher
Chief Financial Officer
(Principal Financial Officer)


Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Robert Bodor, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Proto Labs, Inc. on Form 10-Q for the fiscal quarter ended September 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Proto Labs, Inc.
Date: November 7, 2024
By:/s/ Robert Bodor
Name:Robert Bodor
Title:President and Chief Executive Officer
I, Daniel Schumacher, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Proto Labs, Inc. on Form 10-Q for the fiscal quarter ended September 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Proto Labs, Inc.
Date: November 7, 2024
By:/s/ Daniel Schumacher
Name:Daniel Schumacher
Title:Chief Financial Officer

v3.24.3
Cover - shares
 9 Months Ended
Sep. 30, 2024
Oct. 28, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-35435  
Entity Registrant Name Proto Labs, Inc.  
Entity Incorporation, State or Country Code MN  
Entity Tax Identification Number 41-1939628  
Entity Address, Address Line One 5540 Pioneer Creek Drive  
Entity Address, City or Town Maple Plain  
Entity Address, State or Province MN  
Entity Address, Postal Zip Code 55359  
City Area Code 763  
Local Phone Number 479-3680  
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share  
Trading Symbol PRLB  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   24,510,076
Entity Central Index Key 0001443669  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
v3.24.3
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 87,873 $ 83,790
Short-term marketable securities 12,638 19,013
Accounts receivable, net of allowance for doubtful accounts of $2,261 and $2,499 as of September 30, 2024, and December 31, 2023, respectively 69,464 72,848
Inventory 12,415 13,657
Income taxes receivable 665 2,228
Prepaid expenses and other current assets 10,019 9,124
Total current assets 193,074 200,660
Property and equipment, net 237,942 253,655
Goodwill 273,991 273,991
Other intangible assets, net 22,890 25,584
Long-term marketable securities 17,120 8,019
Operating lease assets 3,519 4,628
Finance lease assets 759 960
Other long-term assets 4,491 4,856
Total assets 753,786 772,353
Current liabilities    
Accounts payable 15,004 15,636
Accrued compensation 17,549 15,292
Accrued liabilities and other 18,455 16,872
Current operating lease liabilities 1,450 1,585
Current finance lease liabilities 306 296
Income taxes payable 994 0
Total current liabilities 53,758 49,681
Long-term operating lease liabilities 1,979 3,008
Long-term finance lease liabilities 365 595
Long-term deferred tax liabilities 12,688 18,742
Other long-term liabilities 5,003 5,032
Total liabilities 73,793 77,058
Shareholders' equity    
Preferred stock, $0.001 par value, authorized 10,000,000 shares; issued and outstanding 0 shares as of each of September 30, 2024, and December 31, 2023 0 0
Common stock, $0.001 par value, authorized 150,000,000 shares; issued and outstanding 24,510,076 and 25,721,957 shares as of September 30, 2024, and December 31, 2023, respectively 25 26
Additional paid-in capital 454,025 466,884
Retained earnings 252,795 256,398
Accumulated other comprehensive loss (26,852) (28,013)
Total shareholders' equity 679,993 695,295
Total liabilities and shareholders' equity $ 753,786 $ 772,353
v3.24.3
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for credit loss, current $ 2,261 $ 2,499
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 24,510,076 25,721,957
Common stock, outstanding (in shares) 24,510,076 25,721,957
v3.24.3
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statements of Operations:        
Revenue $ 125,619 $ 130,705 $ 379,140 $ 378,829
Cost of revenue 68,389 71,423 207,897 212,648
Gross profit 57,230 59,282 171,243 166,181
Operating expenses        
Marketing and sales 22,619 21,682 69,070 65,863
Research and development 9,772 10,105 31,600 30,647
General and administrative 16,259 17,058 49,167 49,713
Closure of Japan business 0 22 0 186
Total operating expenses 48,650 48,867 149,837 146,409
Income from operations 8,580 10,415 21,406 19,772
Other income (loss), net 1,288 320 3,548 (1,758)
Income before income taxes 9,868 10,735 24,954 18,014
Provision for income taxes 2,679 2,781 7,957 7,784
Net income $ 7,189 $ 7,954 $ 16,997 $ 10,230
Net income per share:        
Basic (in dollars per share) $ 0.29 $ 0.31 $ 0.67 $ 0.39
Diluted (in dollars per share) $ 0.29 $ 0.31 $ 0.67 $ 0.39
Shares used to compute net income per share:        
Basic (in shares) 24,980,536 26,023,830 25,304,985 26,296,304
Diluted (in shares) 25,022,485 26,028,456 25,382,280 26,327,606
Comprehensive Income (net of tax)        
Comprehensive income $ 9,769 $ 6,887 $ 18,158 $ 14,297
v3.24.3
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2022   26,888,425      
Beginning balance at Dec. 31, 2022 $ 697,648 $ 27 $ 473,740 $ 258,236 $ (34,355)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued on exercise of options and other, net of shares withheld for tax obligations (in shares)   26,798      
Common shares issued on exercise of options and other, net of shares withheld for tax obligations (401)   (401)    
Stock-based compensation expense 3,695   3,695    
Repurchases of common stock (in shares)   (712,500)      
Repurchases of common stock (21,325) $ (1) (11,849) (9,475)  
Net income (loss) 2,659     2,659  
Other comprehensive income          
Foreign currency translation adjustment 527       527
Net unrealized gains (losses) on investments in securities 334       334
Comprehensive income 3,520        
Ending balance (in shares) at Mar. 31, 2023   26,202,723      
Ending balance at Mar. 31, 2023 683,137 $ 26 465,185 251,420 (33,494)
Beginning balance (in shares) at Dec. 31, 2022   26,888,425      
Beginning balance at Dec. 31, 2022 697,648 $ 27 473,740 258,236 (34,355)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) 10,230        
Other comprehensive income          
Comprehensive income 14,297        
Ending balance (in shares) at Sep. 30, 2023   25,785,903      
Ending balance at Sep. 30, 2023 684,922 $ 26 463,908 251,276 (30,288)
Beginning balance (in shares) at Mar. 31, 2023   26,202,723      
Beginning balance at Mar. 31, 2023 683,137 $ 26 465,185 251,420 (33,494)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued on exercise of options and other, net of shares withheld for tax obligations (in shares)   169,229      
Common shares issued on exercise of options and other, net of shares withheld for tax obligations 962   962    
Stock-based compensation expense 3,675   3,675    
Repurchases of common stock (in shares)   (276,518)      
Repurchases of common stock (8,979)   (4,872) (4,107)  
Net income (loss) (383)     (383)  
Other comprehensive income          
Foreign currency translation adjustment 4,254       4,254
Net unrealized gains (losses) on investments in securities 19       19
Comprehensive income 3,890        
Ending balance (in shares) at Jun. 30, 2023   26,095,434      
Ending balance at Jun. 30, 2023 682,685 $ 26 464,950 246,930 (29,221)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued on exercise of options and other, net of shares withheld for tax obligations (in shares)   1,037      
Common shares issued on exercise of options and other, net of shares withheld for tax obligations (11)   (11)    
Stock-based compensation expense 4,441   4,441    
Repurchases of common stock (in shares)   (310,568)      
Repurchases of common stock (9,080)   (5,472) (3,608)  
Net income (loss) 7,954     7,954  
Other comprehensive income          
Foreign currency translation adjustment (1,307)       (1,307)
Net unrealized gains (losses) on investments in securities 240       240
Comprehensive income 6,887        
Ending balance (in shares) at Sep. 30, 2023   25,785,903      
Ending balance at Sep. 30, 2023 $ 684,922 $ 26 463,908 251,276 (30,288)
Beginning balance (in shares) at Dec. 31, 2023 25,721,957 25,721,957      
Beginning balance at Dec. 31, 2023 $ 695,295 $ 26 466,884 256,398 (28,013)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued on exercise of options and other, net of shares withheld for tax obligations (in shares)   29,974      
Common shares issued on exercise of options and other, net of shares withheld for tax obligations (533)   (533)    
Stock-based compensation expense 4,276   4,276    
Repurchases of common stock and other (in shares)   (435,861)      
Repurchases of common stock and other (16,164)   (7,912) (8,252)  
Net income (loss) 5,268     5,268  
Other comprehensive income          
Foreign currency translation adjustment (925)       (925)
Net unrealized gains (losses) on investments in securities 93       93
Comprehensive income 4,436        
Ending balance (in shares) at Mar. 31, 2024   25,316,070      
Ending balance at Mar. 31, 2024 $ 687,310 $ 26 462,715 253,414 (28,845)
Beginning balance (in shares) at Dec. 31, 2023 25,721,957 25,721,957      
Beginning balance at Dec. 31, 2023 $ 695,295 $ 26 466,884 256,398 (28,013)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) 16,997        
Other comprehensive income          
Comprehensive income $ 18,158        
Ending balance (in shares) at Sep. 30, 2024 24,510,076 24,510,076      
Ending balance at Sep. 30, 2024 $ 679,993 $ 25 454,025 252,795 (26,852)
Beginning balance (in shares) at Mar. 31, 2024   25,316,070      
Beginning balance at Mar. 31, 2024 687,310 $ 26 462,715 253,414 (28,845)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued on exercise of options and other, net of shares withheld for tax obligations (in shares)   176,780      
Common shares issued on exercise of options and other, net of shares withheld for tax obligations 707   707    
Stock-based compensation expense 4,244   4,244    
Repurchases of common stock and other (in shares)   (345,234)      
Repurchases of common stock and other (10,978)   (6,266) (4,712)  
Net income (loss) 4,540     4,540  
Other comprehensive income          
Foreign currency translation adjustment (678)       (678)
Net unrealized gains (losses) on investments in securities 91       91
Comprehensive income 3,953        
Ending balance (in shares) at Jun. 30, 2024   25,147,616      
Ending balance at Jun. 30, 2024 685,236 $ 26 461,400 253,242 (29,432)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,196   4,196    
Repurchases of common stock and other (in shares)   (637,540)      
Repurchases of common stock and other (19,208) $ (1) (11,571) (7,636)  
Net income (loss) 7,189     7,189  
Other comprehensive income          
Foreign currency translation adjustment 2,430       2,430
Net unrealized gains (losses) on investments in securities 150       150
Comprehensive income $ 9,769        
Ending balance (in shares) at Sep. 30, 2024 24,510,076 24,510,076      
Ending balance at Sep. 30, 2024 $ 679,993 $ 25 $ 454,025 $ 252,795 $ (26,852)
v3.24.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Operating activities    
Net income $ 16,997 $ 10,230
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 26,984 28,213
Stock-based compensation expense 12,716 11,811
Deferred taxes (6,140) (9,197)
Interest on finance lease obligations 26 859
Loss on impairment of equipment 256 0
Loss on foreign currency translation 0 3,906
Gain on disposal of property and equipment (24) (498)
Other 103 122
Changes in operating assets and liabilities:    
Accounts receivable 4,581 (3,058)
Inventories 1,321 (150)
Prepaid expenses and other (312) 4,127
Income taxes 2,583 4,693
Accounts payable (2,709) 746
Accrued liabilities and other 4,153 4,242
Net cash provided by operating activities 60,535 56,046
Investing activities    
Purchases of property, equipment and other capital assets (8,339) (9,935)
Proceeds from sales of property, equipment and other capital assets 34 693
Purchases of marketable securities (18,087) 0
Proceeds from call redemptions and maturities of marketable securities 15,709 19,115
Net cash (used in) provided by investing activities (10,683) 9,873
Financing activities    
Proceeds from exercises of stock options and employee stock purchases 2,094 1,986
Purchases of shares withheld for tax obligations (1,920) (1,436)
Repurchases of common stock (45,958) (39,053)
Principal repayments of finance lease obligations (220) (234)
Net cash used in financing activities (46,004) (38,737)
Effect of exchange rate changes on cash and cash equivalents 235 (244)
Net increase in cash and cash equivalents 4,083 26,938
Cash and cash equivalents, beginning of period 83,790 56,558
Cash and cash equivalents, end of period $ 87,873 $ 83,496
v3.24.3
Basis of Presentation
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The unaudited interim Consolidated Financial Statements of Proto Labs, Inc. (Protolabs, the Company, we, us or our) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying financial statements reflect all adjustments necessary for a fair presentation of the Company’s statements of financial position, results of operations and cash flows for the periods presented. Except as otherwise disclosed herein, these adjustments consist of normal, recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (SEC) on February 16, 2024.
The accompanying Consolidated Balance Sheet as of December 31, 2023 was derived from the audited Consolidated Financial Statements but does not include all disclosures required by U.S. GAAP for a full set of financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K filed on February 16, 2024 as referenced above.
v3.24.3
Recent Accounting Pronouncements
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Recent Accounting Pronouncements Recent Accounting Pronouncements
The Company did not recently adopt any accounting pronouncements that had a material impact on the Company's Consolidated Financial Statements.
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, that enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The Company is required to adopt this guidance for its annual year ending December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its disclosures.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, that updates reportable segment disclosure requirements primarily through enhanced disclosures about significant expenses and information used to assess segment performance on an annual and interim basis. The Company is required to adopt this guidance for its annual year ending December 31, 2024 and all interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its disclosures.
v3.24.3
Net Income per Common Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Net Income per Common Share Net Income per Common Share
Basic net income per share is computed based on the weighted-average number of common shares outstanding. Diluted net income per share is computed based on the weighted-average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. Performance stock units are excluded from the calculation of dilutive potential common shares until the performance conditions have been satisfied. Anti-dilutive options were excluded from the calculation of diluted weighted average shares outstanding and were 466,127 and 393,592 for the three months ended September 30, 2024 and 2023, respectively, and 450,275 and 372,353 for the nine months ended September 30, 2024 and 2023, respectively.
The table below sets forth the computation of basic and diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands, except share and per share amounts)2024202320242023
Net income$7,189 $7,954 $16,997 $10,230 
Basic - weighted-average shares outstanding:24,980,53626,023,83025,304,98526,296,304
Effect of dilutive securities:
Employee stock options and other41,9494,62677,29531,302
Diluted - weighted-average shares outstanding:25,022,48526,028,45625,382,28026,327,606
Net income per share:
Basic$0.29 $0.31 $0.67 $0.39 
Diluted$0.29 $0.31 $0.67 $0.39 
v3.24.3
Goodwill and Other Intangible Assets
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets
There were no changes in the carrying amount of goodwill during the three and nine months ended September 30, 2024.
Intangible assets other than goodwill at September 30, 2024 and December 31, 2023 were as follows:
September 30, 2024December 31, 2023Useful
Life (in years)		Weighted Average
Useful Life Remaining
(in years)
(in thousands)GrossAccumulated
Amortization		NetGrossAccumulated
Amortization		Net
Intangible assets with finite lives:
Marketing assets$930 $(930)$— $930 $(900)$30 10.00.0
Non-compete agreement837 (688)149 835 (603)232 
2.0 - 5.0
0.9
Software technology13,229 (8,781)4,448 13,229 (7,752)5,477 10.03.3
Software platform26,481 (8,188)18,293 26,373 (6,575)19,798 12.08.3
Tradenames356 (356)— 354 (347)7 3.00.0
Customer relationships12,232 (12,232)— 12,223 (12,183)40 
3.0 - 9.0
0.0
Total intangible assets$54,065 $(31,175)$22,890 $53,944 $(28,360)$25,584 
Intangible assets allocated to the Protolabs Network entities consisted of intangible assets of €11.6 million in Europe and $16.6 million in the United States as of the date of the acquisition. The Euro denominated intangible assets are translated at the end of each period using the current exchange rates resulting in a foreign currency translation adjustment that is recorded as a component of Other Comprehensive Income. Foreign currency unrealized losses related to intangible assets were $1.2 million and $1.3 million as of September 30, 2024 and December 31, 2023, respectively. Amortization expense for intangible assets was $0.9 million and $1.5 million for each of the three months ended September 30, 2024 and 2023, respectively, and $2.8 million and $4.5 million for each of the nine months ended September 30, 2024 and 2023, respectively.
Estimated aggregated amortization expense based on the current carrying value of the amortizable intangible assets and current exchange rates is as follows:
(in thousands)Estimated Amortization Expense
Remaining 2024$919
20253,676
20263,574
20273,564
20282,195
Thereafter8,962
Total estimated amortization expense$22,890
v3.24.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Accounting Standards Codification, Fair Value Measurement (ASC 820), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The Company's assets and liabilities that are required to be measured or disclosed at fair value on a recurring basis include cash and cash equivalents and marketable securities. The Company’s cash consists of bank deposits and cash equivalents consist primarily of money market mutual funds. The Company determines the fair value of these investments using Level 1 inputs. The Company's marketable securities consist of short-term and long-term agency, municipal, corporate and other debt securities. Fair value for the corporate debt securities is primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, U.S. government agency securities, certificates of deposit and U.S. treasury securities are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).
The following table summarizes financial assets as of September 30, 2024 and December 31, 2023 measured at fair value on a recurring basis:
September 30, 2024December 31, 2023
(in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
Financial Assets:
Cash$83,643 $— $— $77,423 $— $— 
Money market mutual fund4,230 $— — 6,367 — — 
Marketable securities20,290 9,468 — 4,482 22,550 — 
Total$108,163 $9,468 $— $88,272 $22,550 $— 
v3.24.3
Marketable Securities
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The Company invests in short-term and long-term agency, municipal, corporate and other debt securities. The securities are categorized as available-for-sale and are recorded at fair value. The following table summarizes information regarding the Company’s short-term and long-term marketable securities as of September 30, 2024 and December 31, 2023:
September 30, 2024
(in thousands)CostUnrealized GainsUnrealized LossesFair Value
U.S. government agency securities$9,817 $— $(72)$9,745 
Corporate debt securities14,242 36 (15)14,263 
U.S. municipal securities5,767 — (17)5,750 
Total marketable securities$29,826 $36 $(104)$29,758 
December 31, 2023
(in thousands)CostUnrealized GainsUnrealized LossesFair Value
U.S. government agency securities$16,798 $— $(278)$16,520 
Corporate debt securities2,511 — (19)2,492 
U.S. municipal securities7,876 — (105)7,771 
Certificates of deposit/time deposits249 — — 249 
Total marketable securities$27,434 $— $(402)$27,032 
Fair values for the corporate debt securities are primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, U.S. government agency securities, certificates of deposit and U.S. treasury securities are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).
Classification of marketable securities as current or non-current is based upon the security’s maturity date as of the date of these financial statements.
The September 30, 2024 balance of available-for-sale debt securities by contractual maturity is shown in the following table at fair value. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
(in thousands)September 30,
2024
Due in one year or less$12,638 
Due after one year through five years17,120 
Total marketable securities$29,758 
v3.24.3
Inventory
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consists primarily of raw materials, which are recorded at the lower of cost and net realizable value using the standard cost method, which approximates first-in, first-out (FIFO) cost. The Company periodically reviews its inventory for slow-moving, damaged and discontinued items and provides allowances to reduce such items identified to their recoverable amounts.
The Company’s inventory consisted of the following as of the dates indicated:
(in thousands)September 30,
2024		December 31,
2023
Total inventory$13,067 $14,319 
Allowance for obsolescence(652)(662)
Inventory, net of allowance$12,415 $13,657 
v3.24.3
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
Under the Amended and Restated Proto Labs Inc. 2022 Long-Term Incentive Plan, the Company has the ability to grant stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, other stock-based awards and cash incentive awards, which was approved by the Company's shareholders at a Special Meeting of Shareholders on August 29, 2022 and was amended and restated by the Company's shareholders at its Annual Meeting of Shareholders on May 23, 2024 (as amended and restated, the 2022 Plan) to increase the number of shares available for issuance pursuant to awards under the 2022 Plan by an additional 430,000 shares, add a minimum vesting requirement, and extend the expiration date so that the term of the 2022 Plan runs for ten years from the date of the shareholder approval. Awards under the 2022 Plan have a maximum term of ten years from the date of grant. The compensation committee may provide that the vesting or payment of any award will be subject to the attainment of specified performance measures in addition to the satisfaction of any continued service requirements and the compensation committee will determine whether such measures have been achieved. The per-share exercise price of stock options and SARs granted under the 2022 Plan generally may not be less than the fair market value of a share of our common stock on the date of the grant.
The Company also has outstanding awards under the 2012 Long-Term Incentive Plan, as amended (the 2012 Plan), although the plan expired in February 2022 and no additional awards have since been or will be made under the 2012 Plan. The 2012 Plan provided the Company the ability to grant stock options, SARs, restricted stock, restricted stock units, other stock-based awards and cash incentive awards. Awards under the 2012 Plan that subsequently expired, were forfeited or cancelled, or settled in cash after August 29, 2022 became available for awards under the 2022 Plan.
Employee Stock Purchase Plan
The Company’s 2012 Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase a variable number of shares of the Company’s common stock each offering period at a discount through payroll deductions of up to 15 percent of their eligible compensation, subject to plan limitations. The ESPP provides for six-month offering periods with a single purchase period ending May 15 and November 15, respectively. At the end of each offering period, employees are able to purchase shares at 85 percent of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period.
Stock-Based Compensation Expense
Stock-based compensation expense was $4.2 million and $4.4 million for the three months ended September 30, 2024 and 2023, respectively, and $12.7 million and $11.8 million for the nine months ended September 30, 2024 and 2023, respectively.
Stock Options
The following table summarizes stock option activity during the nine months ended September 30, 2024:
Stock OptionsWeighted-
Average
Exercise Price
Options outstanding at December 31, 2023371,313$59.92 
Granted139,21533.41 
Exercised——
Forfeited(42,220)64.43 
Expired(5,094)67.78 
Options outstanding at September 30, 2024463,214$51.46 
Exercisable at September 30, 2024189,816$70.28 
The outstanding options generally have a term of ten years. For employees, options granted become exercisable ratably over the vesting period, which is generally a period of four years, beginning on the first anniversary of the grant date, subject to the employee’s continuing service to the Company.
The weighted-average grant date fair value of options that were granted during the nine months ended September 30, 2024 was $18.15.
The following table provides the assumptions used in the Black-Scholes pricing model valuation of options during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate
4.28% - 4.30%
3.55% - 4.55%
Expected life (years)
6.25
2.00 - 6.25
Expected volatility
50.62% - 50.72%
49.23% - 55.92%
Expected dividend yield0%0%
As of September 30, 2024, there was $4.3 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.7 years.
Restricted Stock
Restricted stock awards are share-settled awards and restrictions lapse ratably over the vesting period, which is generally a period from three to four years, beginning on the first anniversary of the grant date, subject to the employee's continuing service to the Company. For the board of directors, restrictions generally lapse in full on the first anniversary of the grant date.
The following table summarizes restricted stock activity during the nine months ended September 30, 2024:
Restricted
Stock		Weighted-
Average
Grant Date
Fair Value
Per Share
Restricted stock at December 31, 2023653,465$45.89 
Granted336,78533.02 
Restrictions lapsed(191,950)54.48 
Forfeited(51,475)39.06 
Restricted stock at September 30, 2024746,825$38.34 
As of September 30, 2024, there was $20.0 million of unrecognized compensation expense related to non-vested restricted stock, which is expected to be recognized over a weighted-average period of 2.7 years.
Performance Stock
Performance stock units (PSUs) are expressed in terms of a target number of PSUs, with anywhere between 0 percent and 200 percent of that target number capable of being earned and vesting at the end of a three-year performance period depending on the Company’s performance in the final year of the performance period and the award recipient’s continued employment. Certain PSUs granted by the Company in 2021 are based on performance conditions and the related compensation cost is based on the probability that the performance conditions will be achieved. The Company’s PSUs granted in 2022, 2023, 2024 and certain PSUs granted in 2021 are based on market conditions and the related compensation cost is based on the fair value at grant date calculated using a Monte Carlo pricing model.
The following table summarizes performance stock activity during the nine months ended September 30, 2024:
Performance
Stock		Weighted-
Average
Grant Date
Fair Value
Per Share
Performance stock at December 31, 2023107,097$74.08 
Granted79,43648.20 
Restrictions lapsed——
Performance change(2,772)227.14 
Forfeited——
Performance stock at September 30, 2024183,761$60.58 
The following table provides the assumptions used in the Monte Carlo pricing model valuation of PSUs during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate4.37%4.35%
Expected life (years)2.882.88
Expected volatility51.40%
58.00%
Expected dividend yield0%0%
As of September 30, 2024, there was $5.3 million of unrecognized compensation expense related to non-vested performance stock, which is expected to be recognized over a weighted-average period of 1.9 years.
Employee Stock Purchase Plan
The following table presents the assumptions used to estimate the fair value of the ESPP during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate
5.07% - 5.16%
4.60% - 4.82%
Expected life (months)6.006.00
Expected volatility
30.97% - 47.92%
47.38% - 67.84%
Expected dividend yield0%0%
v3.24.3
Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2024
Regulated Operations [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
Other comprehensive income (loss) is comprised of foreign currency translation adjustments and net unrealized gains (losses) on investments in securities.
The following table presents the changes in accumulated other comprehensive income (loss) balances during the three and nine months ended September 30, 2024 and 2023:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Balance at beginning of period$(29,432)$(29,221)$(28,013)$(34,355)
Foreign currency translation adjustments
Other comprehensive income (loss) before reclassifications2,430 (1,307)827 (432)
Amounts reclassified from accumulated other comprehensive loss— — — 3,906 
Net current-period other comprehensive income (loss)2,430 (1,307)827 3,474 
Net unrealized gains (loss) on investments in securities
Other comprehensive income before reclassifications150 240 334 593 
Amounts reclassified from accumulated other comprehensive loss— — — — 
Net current-period other comprehensive income150 240 334 593 
Balance at end of period$(26,852)$(30,288)$(26,852)$(30,288)
v3.24.3
Income Taxes
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company is subject to income tax in multiple jurisdictions and the use of estimates is required to determine the provision for income taxes. For the three months ended September 30, 2024 and 2023, the Company recorded an income tax provision of $2.7 million and $2.8 million, respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded an income tax provision of $8.0 million and $7.8 million, respectively. The income tax provision is based on the estimated annual effective tax rate for the year applied to pre-tax income. The effective income tax rate for the three months ended September 30, 2024 was 27.1 percent compared to 25.9 percent in the same period of the prior year. The effective tax rate increased by 1.2 percent for the three months ended September 30, 2024 when compared to the same period in 2023, primarily due to a reduction in expenditures that qualify for the research and development credit. The effective income tax rate for the nine months ended September 30, 2024 was 31.9 percent compared to 43.2 percent in the same period of the prior year. The effective tax rate decreased by 11.3 percent for the nine months ended September 30, 2024 when compared to the same period in 2023, primarily due to the prior year one-time tax impact of the foreign currency translation loss from the closure of our Japan business.
The effective income tax rate for the three and nine months ended September 30, 2024 differs from the U.S. federal statutory rate of 21.0 percent due to various factors, including operating in multiple state and foreign jurisdictions partially offset by tax credits for which the Company qualifies.
The Company had unrecognized tax benefits totaling $3.7 million as of September 30, 2024 and $3.6 million as of December 31, 2023, respectively, that if recognized would result in a reduction of the Company’s effective tax rate. The liabilities are classified as other long-term liabilities in the accompanying consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters in income tax expense and reports the liability in current or long-term income taxes payable as appropriate.
v3.24.3
Segment Reporting
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s reportable segments are based on the internal reporting used by the Company’s Chief Executive Officer, who is the chief operating decision maker (CODM), to assess operating performance and make decisions about the allocation of resources. The Corporate Unallocated and Japan category includes non-reportable segments, as well as research and development and general and administrative costs, that the Company does not allocate directly to its operating segments.
Intercompany transactions primarily relate to intercontinental activity and have been eliminated and are excluded from the reported amounts. The difference between income from operations and pre-tax income relates to foreign currency-related gains and losses and interest income on cash balances and investments, which are not allocated to business segments.
Revenue and income from operations by reportable segment for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(dollars in thousands)2024202320242023
Revenue:
United States$99,571 $103,940 $299,593 $298,007 
Europe26,048 26,765 79,547 80,822 
Total revenue$125,619 $130,705 $379,140 $378,829 
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Income (Loss) from Operations:
United States$25,687 $27,178 $76,260 $69,713 
Europe(2,398)(3,006)(6,574)(8,870)
Corporate Unallocated and Japan(14,709)(13,757)(48,280)(41,071)
Total Income from Operations$8,580 $10,415 $21,406 $19,772 
Total long-lived assets at September 30, 2024 and December 31, 2023 were as follows:
(in thousands)September 30,
2024		December 31,
2023
Total long-lived assets:
United States$187,130 $201,388 
Europe50,812 52,267 
Total Long-lived Assets$237,942 $253,655 
Revenue by product line for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(dollars in thousands)2024202320242023
Revenue:
Injection Molding$46,831 $51,688 $148,574 $152,455 
CNC Machining53,327 52,916 154,498 149,317 
3D Printing21,437 21,622 64,300 63,952 
Sheet Metal3,743 4,291 11,218 12,478 
Other Revenue281 188 550 627 
Total Revenue$125,619 $130,705 $379,140 $378,829 
v3.24.3
Subsequent Event
 9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
Subsequent Event Subsequent Event
On October 21, 2024, the Board of Directors of Proto Labs, Inc. approved a plan related to the Company's manufacturing facilities in Germany. The plan includes the closure of the Company's prototype injection molding manufacturing facility in Eschenlohe, Germany, and the discontinuation of Direct Metal Laser Sintering 3D printing services through its Putzbrunn, Germany, 3D printing facility. Affected employees in Germany will receive severance and other transition assistance that meet or exceed local requirements. The Company expects to substantially complete the plan within the next year.
The Company will continue offering all its manufacturing services to customers across Europe, including injection molding and metal 3D printing. These services will be fulfilled through internal manufacturing facilities and a network of manufacturing partners, consistent with the Company's recently announced global operations organization.

The approved plan is expected to lead to total restructuring charges in the range of $4.5 million to $6.0 million consisting of approximately $2.5 million to $3.5 million in severance and other employee-related costs, and $2.0 million to $2.5 million in fixed asset and facility related write-down expenses. The company expects to incur approximately $4.0 million of the total restructuring charge in the fourth quarter of 2024, with the remaining charge to be incurred throughout the remainder of the restructuring process.

The total cash expenditures associated with the plan are expected to be in the range of $3.0 million to $4.0 million, consisting primarily of severance and other employee related costs.
v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure                
Net income (loss) $ 7,189 $ 4,540 $ 5,268 $ 7,954 $ (383) $ 2,659 $ 16,997 $ 10,230
v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.3
Net Income per Common Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The table below sets forth the computation of basic and diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands, except share and per share amounts)2024202320242023
Net income$7,189 $7,954 $16,997 $10,230 
Basic - weighted-average shares outstanding:24,980,53626,023,83025,304,98526,296,304
Effect of dilutive securities:
Employee stock options and other41,9494,62677,29531,302
Diluted - weighted-average shares outstanding:25,022,48526,028,45625,382,28026,327,606
Net income per share:
Basic$0.29 $0.31 $0.67 $0.39 
Diluted$0.29 $0.31 $0.67 $0.39 
v3.24.3
Goodwill and Other Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets other than goodwill at September 30, 2024 and December 31, 2023 were as follows:
September 30, 2024December 31, 2023Useful
Life (in years)		Weighted Average
Useful Life Remaining
(in years)
(in thousands)GrossAccumulated
Amortization		NetGrossAccumulated
Amortization		Net
Intangible assets with finite lives:
Marketing assets$930 $(930)$— $930 $(900)$30 10.00.0
Non-compete agreement837 (688)149 835 (603)232 
2.0 - 5.0
0.9
Software technology13,229 (8,781)4,448 13,229 (7,752)5,477 10.03.3
Software platform26,481 (8,188)18,293 26,373 (6,575)19,798 12.08.3
Tradenames356 (356)— 354 (347)7 3.00.0
Customer relationships12,232 (12,232)— 12,223 (12,183)40 
3.0 - 9.0
0.0
Total intangible assets$54,065 $(31,175)$22,890 $53,944 $(28,360)$25,584 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated aggregated amortization expense based on the current carrying value of the amortizable intangible assets and current exchange rates is as follows:
(in thousands)Estimated Amortization Expense
Remaining 2024$919
20253,676
20263,574
20273,564
20282,195
Thereafter8,962
Total estimated amortization expense$22,890
v3.24.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring Basis
The following table summarizes financial assets as of September 30, 2024 and December 31, 2023 measured at fair value on a recurring basis:
September 30, 2024December 31, 2023
(in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
Financial Assets:
Cash$83,643 $— $— $77,423 $— $— 
Money market mutual fund4,230 $— — 6,367 — — 
Marketable securities20,290 9,468 — 4,482 22,550 — 
Total$108,163 $9,468 $— $88,272 $22,550 $— 
v3.24.3
Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Debt Securities, Available-for-Sale The following table summarizes information regarding the Company’s short-term and long-term marketable securities as of September 30, 2024 and December 31, 2023:
September 30, 2024
(in thousands)CostUnrealized GainsUnrealized LossesFair Value
U.S. government agency securities$9,817 $— $(72)$9,745 
Corporate debt securities14,242 36 (15)14,263 
U.S. municipal securities5,767 — (17)5,750 
Total marketable securities$29,826 $36 $(104)$29,758 
December 31, 2023
(in thousands)CostUnrealized GainsUnrealized LossesFair Value
U.S. government agency securities$16,798 $— $(278)$16,520 
Corporate debt securities2,511 — (19)2,492 
U.S. municipal securities7,876 — (105)7,771 
Certificates of deposit/time deposits249 — — 249 
Total marketable securities$27,434 $— $(402)$27,032 
Investments Classified by Contractual Maturity Date
The September 30, 2024 balance of available-for-sale debt securities by contractual maturity is shown in the following table at fair value. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
(in thousands)September 30,
2024
Due in one year or less$12,638 
Due after one year through five years17,120 
Total marketable securities$29,758 
v3.24.3
Inventory (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
The Company’s inventory consisted of the following as of the dates indicated:
(in thousands)September 30,
2024		December 31,
2023
Total inventory$13,067 $14,319 
Allowance for obsolescence(652)(662)
Inventory, net of allowance$12,415 $13,657 
v3.24.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Payment Arrangement, Option, Activity
The following table summarizes stock option activity during the nine months ended September 30, 2024:
Stock OptionsWeighted-
Average
Exercise Price
Options outstanding at December 31, 2023371,313$59.92 
Granted139,21533.41 
Exercised——
Forfeited(42,220)64.43 
Expired(5,094)67.78 
Options outstanding at September 30, 2024463,214$51.46 
Exercisable at September 30, 2024189,816$70.28 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions
The following table provides the assumptions used in the Black-Scholes pricing model valuation of options during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate
4.28% - 4.30%
3.55% - 4.55%
Expected life (years)
6.25
2.00 - 6.25
Expected volatility
50.62% - 50.72%
49.23% - 55.92%
Expected dividend yield0%0%
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity
The following table summarizes restricted stock activity during the nine months ended September 30, 2024:
Restricted
Stock		Weighted-
Average
Grant Date
Fair Value
Per Share
Restricted stock at December 31, 2023653,465$45.89 
Granted336,78533.02 
Restrictions lapsed(191,950)54.48 
Forfeited(51,475)39.06 
Restricted stock at September 30, 2024746,825$38.34 
Schedule of Nonvested Performance-Based Units Activity
The following table summarizes performance stock activity during the nine months ended September 30, 2024:
Performance
Stock		Weighted-
Average
Grant Date
Fair Value
Per Share
Performance stock at December 31, 2023107,097$74.08 
Granted79,43648.20 
Restrictions lapsed——
Performance change(2,772)227.14 
Forfeited——
Performance stock at September 30, 2024183,761$60.58 
Schedule of Share-based Payment Award, Awards Other Than Stock Options, Valuation Assumptions
The following table provides the assumptions used in the Monte Carlo pricing model valuation of PSUs during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate4.37%4.35%
Expected life (years)2.882.88
Expected volatility51.40%
58.00%
Expected dividend yield0%0%
Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions
The following table presents the assumptions used to estimate the fair value of the ESPP during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
20242023
Risk-free interest rate
5.07% - 5.16%
4.60% - 4.82%
Expected life (months)6.006.00
Expected volatility
30.97% - 47.92%
47.38% - 67.84%
Expected dividend yield0%0%
v3.24.3
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2024
Regulated Operations [Abstract]  
Comprehensive Income (Loss)
The following table presents the changes in accumulated other comprehensive income (loss) balances during the three and nine months ended September 30, 2024 and 2023:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Balance at beginning of period$(29,432)$(29,221)$(28,013)$(34,355)
Foreign currency translation adjustments
Other comprehensive income (loss) before reclassifications2,430 (1,307)827 (432)
Amounts reclassified from accumulated other comprehensive loss— — — 3,906 
Net current-period other comprehensive income (loss)2,430 (1,307)827 3,474 
Net unrealized gains (loss) on investments in securities
Other comprehensive income before reclassifications150 240 334 593 
Amounts reclassified from accumulated other comprehensive loss— — — — 
Net current-period other comprehensive income150 240 334 593 
Balance at end of period$(26,852)$(30,288)$(26,852)$(30,288)
v3.24.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Areas
Revenue and income from operations by reportable segment for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(dollars in thousands)2024202320242023
Revenue:
United States$99,571 $103,940 $299,593 $298,007 
Europe26,048 26,765 79,547 80,822 
Total revenue$125,619 $130,705 $379,140 $378,829 
Income from Operations by Geographic Area
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Income (Loss) from Operations:
United States$25,687 $27,178 $76,260 $69,713 
Europe(2,398)(3,006)(6,574)(8,870)
Corporate Unallocated and Japan(14,709)(13,757)(48,280)(41,071)
Total Income from Operations$8,580 $10,415 $21,406 $19,772 
Long-Lived Assets by Geographic Areas
Total long-lived assets at September 30, 2024 and December 31, 2023 were as follows:
(in thousands)September 30,
2024		December 31,
2023
Total long-lived assets:
United States$187,130 $201,388 
Europe50,812 52,267 
Total Long-lived Assets$237,942 $253,655 
Disaggregation of Revenue
Revenue by product line for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(dollars in thousands)2024202320242023
Revenue:
Injection Molding$46,831 $51,688 $148,574 $152,455 
CNC Machining53,327 52,916 154,498 149,317 
3D Printing21,437 21,622 64,300 63,952 
Sheet Metal3,743 4,291 11,218 12,478 
Other Revenue281 188 550 627 
Total Revenue$125,619 $130,705 $379,140 $378,829 
v3.24.3
Net Income per Common Share - Narrative (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Earnings Per Share [Abstract]        
Anti-dilutive options excluded from calculation of diluted weighted average shares outstanding (in shares) 466,127 393,592 450,275 372,353
v3.24.3
Net Income per Common Share -Schedule of Computation Of Basic and Diluted Net Income Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Earnings Per Share [Abstract]                
Net income $ 7,189 $ 4,540 $ 5,268 $ 7,954 $ (383) $ 2,659 $ 16,997 $ 10,230
Basic - weighted-average shares outstanding (in shares) 24,980,536     26,023,830     25,304,985 26,296,304
Effect of dilutive securities:                
Employee stock options and other (in shares) 41,949     4,626     77,295 31,302
Diluted - weighted-average shares outstanding (in shares) 25,022,485     26,028,456     25,382,280 26,327,606
Net income per share:                
Basic (in dollars per share) $ 0.29     $ 0.31     $ 0.67 $ 0.39
Diluted (in dollars per share) $ 0.29     $ 0.31     $ 0.67 $ 0.39
v3.24.3
Goodwill and Other Intangible Assets - Schedule of Intangible Assets Other Than Goodwill (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross $ 54,065 $ 53,944
Accumulated Amortization (31,175) (28,360)
Net 22,890 25,584
Marketing assets    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross 930 930
Accumulated Amortization (930) (900)
Net $ 0 30
Useful Life (in years) 10 years  
Weighted Average Useful Life Remaining (in years) 0 years  
Non-compete agreement    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross $ 837 835
Accumulated Amortization (688) (603)
Net $ 149 232
Weighted Average Useful Life Remaining (in years) 10 months 24 days  
Non-compete agreement | Minimum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful Life (in years) 2 years  
Non-compete agreement | Maximum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful Life (in years) 5 years  
Software technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross $ 13,229 13,229
Accumulated Amortization (8,781) (7,752)
Net $ 4,448 5,477
Useful Life (in years) 10 years  
Weighted Average Useful Life Remaining (in years) 3 years 3 months 18 days  
Software platform    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross $ 26,481 26,373
Accumulated Amortization (8,188) (6,575)
Net $ 18,293 19,798
Useful Life (in years) 12 years  
Weighted Average Useful Life Remaining (in years) 8 years 3 months 18 days  
Tradenames    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross $ 356 354
Accumulated Amortization (356) (347)
Net $ 0 7
Useful Life (in years) 3 years  
Weighted Average Useful Life Remaining (in years) 0 years  
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross $ 12,232 12,223
Accumulated Amortization (12,232) (12,183)
Net $ 0 $ 40
Weighted Average Useful Life Remaining (in years) 0 years  
Customer relationships | Minimum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful Life (in years) 3 years  
Customer relationships | Maximum    
Acquired Finite-Lived Intangible Assets [Line Items]    
Useful Life (in years) 9 years  
v3.24.3
Goodwill and Other Intangible Assets - Narrative (Details)
€ in Millions, $ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 22, 2021
EUR (€)
Jan. 22, 2021
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]              
Foreign currency losses         $ 1.2   $ 1.3
Amortization expense for intangible assets     $ 0.9 $ 1.5 $ 2.8 $ 4.5  
Europe | 3D Hubs, Inc. (Hubs)              
Acquired Finite-Lived Intangible Assets [Line Items]              
Intangible assets acquired | € € 11.6            
United States | 3D Hubs, Inc. (Hubs)              
Acquired Finite-Lived Intangible Assets [Line Items]              
Intangible assets acquired   $ 16.6          
v3.24.3
Goodwill and Other Intangible Assets - Future Amortization Expense (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]    
Remaining 2024 $ 919  
2025 3,676  
2026 3,574  
2027 3,564  
2028 2,195  
Thereafter 8,962  
Net $ 22,890 $ 25,584
v3.24.3
Fair Value Measurements - Financial Assets Measured At Fair Value On A Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Financial Assets:    
Debt securities, available-for-sale $ 29,758 $ 27,032
Level 1 | Fair Value, Recurring    
Financial Assets:    
Debt securities, available-for-sale 20,290 4,482
Total 108,163 88,272
Level 2 | Fair Value, Recurring    
Financial Assets:    
Debt securities, available-for-sale 9,468 22,550
Total 9,468 22,550
Level 3 | Fair Value, Recurring    
Financial Assets:    
Debt securities, available-for-sale 0 0
Total 0 0
Cash | Level 1 | Fair Value, Recurring    
Financial Assets:    
Cash and cash equivalents 83,643 77,423
Cash | Level 2 | Fair Value, Recurring    
Financial Assets:    
Cash and cash equivalents 0 0
Cash | Level 3 | Fair Value, Recurring    
Financial Assets:    
Cash and cash equivalents 0 0
Money market mutual fund | Level 1 | Fair Value, Recurring    
Financial Assets:    
Cash and cash equivalents 4,230 6,367
Money market mutual fund | Level 2 | Fair Value, Recurring    
Financial Assets:    
Cash and cash equivalents 0 0
Money market mutual fund | Level 3 | Fair Value, Recurring    
Financial Assets:    
Cash and cash equivalents $ 0 $ 0
v3.24.3
Marketable Securities - Short-Term and Long-Term Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Cost $ 29,826 $ 27,434
Unrealized Gains 36 0
Unrealized Losses (104) (402)
Fair Value 29,758 27,032
U.S. government agency securities    
Debt Securities, Available-for-Sale [Line Items]    
Cost 9,817 16,798
Unrealized Gains 0 0
Unrealized Losses (72) (278)
Fair Value 9,745 16,520
Corporate debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Cost 14,242 2,511
Unrealized Gains 36 0
Unrealized Losses (15) (19)
Fair Value 14,263 2,492
U.S. municipal securities    
Debt Securities, Available-for-Sale [Line Items]    
Cost 5,767 7,876
Unrealized Gains 0 0
Unrealized Losses (17) (105)
Fair Value $ 5,750 7,771
Certificates of deposit/time deposits    
Debt Securities, Available-for-Sale [Line Items]    
Cost   249
Unrealized Gains   0
Unrealized Losses   0
Fair Value   $ 249
v3.24.3
Marketable Securities - Maturities of Available-For-Sale Debt Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Due in one year or less $ 12,638  
Due after one year through five years 17,120  
Total marketable securities $ 29,758 $ 27,032
v3.24.3
Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Total inventory $ 13,067 $ 14,319
Allowance for obsolescence (652) (662)
Inventory, net of allowance $ 12,415 $ 13,657
v3.24.3
Stock-Based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
May 23, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Stock-based compensation expense   $ 4.2 $ 4.4 $ 12.7 $ 11.8
Stock-based award, weighted-average grant date fair value (in dollars per share)       $ 18.15  
ESPP          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Discount from market price (in percent)       15.00%  
Offering period (in months)       6 months  
Purchase price of common stock (in percent)       85.00%  
Stock Options          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Stock-based award, term (in years)       10 years  
Stock-based award, vesting period (in years)       4 years  
Stock based award, unrecognized compensation expense   4.3   $ 4.3  
Stock based award, unrecognized compensation expense, period for recognition (in years)       2 years 8 months 12 days  
Restricted Stock          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Stock based award, unrecognized compensation expense   20.0   $ 20.0  
Stock based award, unrecognized compensation expense, period for recognition (in years)       2 years 8 months 12 days  
Restricted Stock | Minimum          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Stock-based award, vesting period (in years)       3 years  
Restricted Stock | Maximum          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Stock-based award, vesting period (in years)       4 years  
Performance Shares          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Stock-based award, vesting period (in years)       3 years  
Stock based award, unrecognized compensation expense   $ 5.3   $ 5.3  
Stock based award, unrecognized compensation expense, period for recognition (in years)       1 year 10 months 24 days  
Percentage of target, capable of being earned and vesting, lower limit   0.00%   0.00%  
Percentage of target, capable of being earned and vesting, upper limit   200.00%   200.00%  
Long-Term Incentive Plan 2022          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Number of shares available for issuance pursuant to awards (in shares) 430,000        
Stock-based award, term (in years)       10 years  
v3.24.3
Stock-Based Compensation - Option Activity (Details)
 9 Months Ended
Sep. 30, 2024
$ / shares
shares
Stock Options  
Options outstanding, beginning balance (in shares) | shares 371,313
Granted (in shares) | shares 139,215
Exercised (in shares) | shares 0
Forfeited (in shares) | shares (42,220)
Expired (in shares) | shares (5,094)
Options outstanding, ending balance (in shares) | shares 463,214
Weighted- Average Exercise Price  
Options outstanding, beginning balance, weighted-average exercise price (in dollars per share) | $ / shares $ 59.92
Granted, weighted-average exercise price (in dollars per share) | $ / shares 33.41
Exercised, weighted-average exercise price (in dollars per share) | $ / shares 0
Forfeited, weighted-average exercise price (in dollars per share) | $ / shares 64.43
Expired, weighted-average exercise price (in dollars per share) | $ / shares 67.78
Options outstanding, ending balance, weighted-average exercise price (in dollars per share) | $ / shares $ 51.46
Additional Disclosures  
Option exercisable (in shares) | shares 189,816
Options exercisable, weighted-average exercise price (in dollars per share) | $ / shares $ 70.28
v3.24.3
Stock-Based Compensation - Weighted Average Assumptions (Details)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Employee Stock Purchase Plan    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Expected life (years) 6 years 6 years
Expected dividend yield 0.00% 0.00%
Stock Options    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Expected life (years) 6 years 3 months  
Expected dividend yield 0.00% 0.00%
Performance Shares    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Risk-free interest rate 4.37% 4.35%
Expected life (years) 2 years 10 months 17 days 2 years 10 months 17 days
Expected volatility 51.40% 58.00%
Expected dividend yield 0.00% 0.00%
Minimum | Employee Stock Purchase Plan    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Risk-free interest rate 5.07% 4.60%
Expected volatility 30.97% 47.38%
Minimum | Stock Options    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Risk-free interest rate 4.28% 3.55%
Expected life (years)   2 years
Expected volatility 50.62% 49.23%
Maximum | Employee Stock Purchase Plan    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Risk-free interest rate 5.16% 4.82%
Expected volatility 47.92% 67.84%
Maximum | Stock Options    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Risk-free interest rate 4.30% 4.55%
Expected life (years)   6 years 3 months
Expected volatility 50.72% 55.92%
v3.24.3
Stock-Based Compensation - Stock Activity (Details)
 9 Months Ended
Sep. 30, 2024
$ / shares
shares
Restricted Stock  
Stock  
Beginning balance (in shares) | shares 653,465
Granted (in shares) | shares 336,785
Restrictions lapsed (in shares) | shares (191,950)
Forfeited (in shares) | shares (51,475)
Ending balance (in shares) | shares 746,825
Weighted- Average Grant Date Fair Value Per Share  
Beginning balance, weighted-average grant date fair value (in dollars per share) | $ / shares $ 45.89
Granted, weighted-average grant date fair value (in dollars per share) | $ / shares 33.02
Restrictions lapsed, weighted-average grant date fair value (in dollars per share) | $ / shares 54.48
Forfeited, weighted-average grant date fair value (in dollars per share) | $ / shares 39.06
Ending balance, weighted-average grant date fair value (in dollars per share) | $ / shares $ 38.34
Performance Shares  
Stock  
Beginning balance (in shares) | shares 107,097
Granted (in shares) | shares 79,436
Restrictions lapsed (in shares) | shares 0
Performance change (in shares) | shares (2,772)
Forfeited (in shares) | shares 0
Ending balance (in shares) | shares 183,761
Weighted- Average Grant Date Fair Value Per Share  
Beginning balance, weighted-average grant date fair value (in dollars per share) | $ / shares $ 74.08
Granted, weighted-average grant date fair value (in dollars per share) | $ / shares 48.20
Restrictions lapsed, weighted-average grant date fair value (in dollars per share) | $ / shares 0
Performance change, weighted-average grant date fair value (in dollars per share) | $ / shares 227.14
Forfeited, weighted-average grant date fair value (in dollars per share) | $ / shares 0
Ending balance, weighted-average grant date fair value (in dollars per share) | $ / shares $ 60.58
v3.24.3
Accumulated Other Comprehensive Income (Loss) - Changes In Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance $ 685,236 $ 682,685 $ 695,295 $ 697,648
Net unrealized gains (loss) on investments in securities        
Ending balance 679,993 684,922 679,993 684,922
Accumulated Other Comprehensive Loss        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance (29,432) (29,221) (28,013) (34,355)
Net unrealized gains (loss) on investments in securities        
Ending balance (26,852) (30,288) (26,852) (30,288)
Foreign currency translation adjustments        
Foreign currency translation adjustments        
Other comprehensive income (loss) before reclassifications 2,430 (1,307) 827 (432)
Amounts reclassified from accumulated other comprehensive loss 0 0 0 3,906
Net unrealized gains (loss) on investments in securities        
Other comprehensive income before reclassifications 2,430 (1,307) 827 (432)
Amounts reclassified from accumulated other comprehensive loss 0 0 0 3,906
Net current-period other comprehensive income (loss) 2,430 (1,307) 827 3,474
Net unrealized gains (loss) on investments in securities        
Foreign currency translation adjustments        
Other comprehensive income (loss) before reclassifications 150 240 334 593
Amounts reclassified from accumulated other comprehensive loss 0 0 0 0
Net unrealized gains (loss) on investments in securities        
Other comprehensive income before reclassifications 150 240 334 593
Amounts reclassified from accumulated other comprehensive loss 0 0 0 0
Net current-period other comprehensive income (loss) $ 150 $ 240 $ 334 $ 593
v3.24.3
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Income Tax Disclosure [Abstract]          
Provision for income taxes $ 2,679 $ 2,781 $ 7,957 $ 7,784  
Effective income tax rate (in percent) 27.10% 25.90% 31.90% 43.20%  
Effective income tax rate, increase (decrease) during period (in percent) 1.20%   (11.30%)    
Federal statutory rate (in percent) 21.00%   21.00%    
Unrecognized tax benefits $ 3,700   $ 3,700   $ 3,600
v3.24.3
Segment Reporting - Revenue by Geographic Areas (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Total revenue $ 125,619 $ 130,705 $ 379,140 $ 378,829
Operating Segments        
Segment Reporting Information [Line Items]        
Total revenue 125,619 130,705 379,140 378,829
Operating Segments | United States        
Segment Reporting Information [Line Items]        
Total revenue 99,571 103,940 299,593 298,007
Operating Segments | Europe        
Segment Reporting Information [Line Items]        
Total revenue $ 26,048 $ 26,765 $ 79,547 $ 80,822
v3.24.3
Segment Reporting - Income From Operation by Geographic Areas (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Total Income from Operations $ 8,580 $ 10,415 $ 21,406 $ 19,772
Operating Segments        
Segment Reporting Information [Line Items]        
Total Income from Operations 8,580 10,415 21,406 19,772
Operating Segments | United States        
Segment Reporting Information [Line Items]        
Total Income from Operations 25,687 27,178 76,260 69,713
Operating Segments | Europe        
Segment Reporting Information [Line Items]        
Total Income from Operations (2,398) (3,006) (6,574) (8,870)
Operating Segments | Corporate Unallocated and Japan        
Segment Reporting Information [Line Items]        
Total Income from Operations $ (14,709) $ (13,757) $ (48,280) $ (41,071)
v3.24.3
Segment Reporting - Long-Lived Assets by Geographic Areas (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Total Long-lived Assets $ 237,942 $ 253,655
Operating Segments    
Segment Reporting Information [Line Items]    
Total Long-lived Assets 237,942 253,655
Operating Segments | United States    
Segment Reporting Information [Line Items]    
Total Long-lived Assets 187,130 201,388
Operating Segments | Europe    
Segment Reporting Information [Line Items]    
Total Long-lived Assets $ 50,812 $ 52,267
v3.24.3
Segment Reporting - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Total revenue $ 125,619 $ 130,705 $ 379,140 $ 378,829
Injection Molding        
Segment Reporting Information [Line Items]        
Total revenue 46,831 51,688 148,574 152,455
CNC Machining        
Segment Reporting Information [Line Items]        
Total revenue 53,327 52,916 154,498 149,317
3D Printing        
Segment Reporting Information [Line Items]        
Total revenue 21,437 21,622 64,300 63,952
Sheet Metal        
Segment Reporting Information [Line Items]        
Total revenue 3,743 4,291 11,218 12,478
Other Revenue        
Segment Reporting Information [Line Items]        
Total revenue $ 281 $ 188 $ 550 $ 627
v3.24.3
Subsequent Event (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2025
Oct. 21, 2024
Forecast      
Subsequent Event [Line Items]      
Restructuring charges $ 4.0    
Minimum | Employee Severance | Forecast      
Subsequent Event [Line Items]      
Payments for restructuring   $ 3.0  
Minimum | Subsequent Event      
Subsequent Event [Line Items]      
Restructuring charge expected to incur     $ 4.5
Minimum | Subsequent Event | Employee Severance      
Subsequent Event [Line Items]      
Restructuring charge expected to incur     2.5
Minimum | Subsequent Event | Facility Closing      
Subsequent Event [Line Items]      
Restructuring charge expected to incur     2.0
Maximum | Employee Severance | Forecast      
Subsequent Event [Line Items]      
Payments for restructuring   $ 4.0  
Maximum | Subsequent Event      
Subsequent Event [Line Items]      
Restructuring charge expected to incur     6.0
Maximum | Subsequent Event | Employee Severance      
Subsequent Event [Line Items]      
Restructuring charge expected to incur     3.5
Maximum | Subsequent Event | Facility Closing      
Subsequent Event [Line Items]      
Restructuring charge expected to incur     $ 2.5
Proto Labs (NYSE:PRLB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Proto Labs Charts.
Proto Labs (NYSE:PRLB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Proto Labs Charts.